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Scientific environment  
This research project was undertaken at the Global Health Priorities research group at 
Department of Global Public Health and Primary Care, University of Bergen. 
Professor Kjell Arne Johansson served as the main supervisor. Professor Ole Frithjof 
Norheim (Adjunct professor, Department of Global Health and Population, Harvard 
T.H. Chan School of Public Health) and Professor Stéphane Verguet (Department of 
Global Health and Population, Harvard T.H. Chan School of Public Health) were the 
co-supervisors.  
This project was financed by the Norwegian Research Council through the Global 





“For they did not make the land theirs by their swords, and it was not their arms 
which kept them safe; but Your right hand, and Your arm, and the light of Your face, 
because You had pleasure in them. You are my King and My God; ordering salvation 
for Jacob. Through you will we overcome our haters; by Your name they will be 
crushed under our feet who are violent against us. I will not put faith in my bow; my 
sword will not be my salvation. But it is you who have been our savior from those 
who were against us, and have put to shame those who had hate us. Our pride is in 
God at all times, to His name we give praise forever” Psalm 44: 3-8. 
Above all, to my Father (አባቴ ለኔ)—my God, my very best Friend, and my 
Everything—words are not enough to tell what You are worth to me. Every living 
cell in my being loves you to death for who You are for me. Thank you for the love, 
the care, the fellowship, the protection, the guidance, the wisdom, the favor, the 
goodness, and all the provisions. I cannot list all, but I know and I know that I am 
absolutely nobody and nothing without You!!! It is all because of you አባቴ—not only 
for this PhD, You deserve the honor for every single goodness in my life! I LOVE 
YOU አባቴ. 
Next, I would like express my gratitude to many who have contributed to my success 
in various ways. 
My main supervisor, Prof. Kjell Arne Johansson, thank you so much for your 
creativity, bright ideas, and enthusiasm, without which it could have not been 
possible to finish this work. You were very kind, flexible, understanding, and always 
ready to help me move forward with the PhD project by all means. Thank you for 
pushing me to keep going even when I felt like ‘uuhhhh’. It has been a great pleasure 
to work with you.  
Prof. Ole Frithjof Norheim, my co-supervisor, for trusting in me and making a way 
for me to pursue this PhD where there was no way. Your insightful ideas and 
suggestions were key to complete this work. Your exemplary professionalism and our 
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technical discussions were among the main sources of motivation for me to go further 
in the field.  
Prof. Stephane Verguet, my co-supervisor, for the critical advice and insights which 
helped to broaden my perspectives. Your support for the “next step” was a key source 
of motivation to press forward during the final miles. Thank you so much. 
Davidson Gwatkin (the first person who e-introduced me with Prof. Ole Norheim) 
Kristine Husøy Onarheim (the first in-person contact with Prof. Ole Norheim), I owe 
you a big time.  
Members of the Global Health Priorities research group at IGS & colleagues: Frode 
Lindemark, Ingrid Miljeteig, Kristine Bærøe, Kristine Husøy Onarheim, Eirok 
Joakim Tranvag, Kristine Tislevoll Eide, Bjarne Robberstad, Dawit Desalegn, Carl 
Tollef Solberg, Eirin Kruger Skaftun, Emily McLean, Solomon Tesseama, Frehiwot 
Berhane Defaye, Mengistu Bekele, Feven Girma, Samuel Dargie, Hilde Marie 
Engjom, Ulrikke Johanne Voltersvik Hernæs, Frida Namnyak Ngalesoni, Gry 
Wester, Jan-Magnus Økland, Nisha Deolalikar and Jeremy Aidem, thank you for the 
technical discussions; and the coffee, the meals, and the laughter that we shared. 
I would also like to extend my appreciation to the admin staff at IGS and CIH for 
their rentless support. My special thanks go to Kjell Rune, Arlend, Nina, Øyvind, 
Therese, Linda, and Borgny (you picked me up from BGO airport the very first day). 
My “housing agents”—Emily, Kristein Onarheim, Janne, Anna, and Frode—you 
have contributed so much to my productivity by upgrading my living condition to 
some of the best spots in Bergen. Thanks a lot. 
Sudha Basnet, for making the first one and half year in Bergen enjoyable.  
Sabi & Melaku (my family in Bergen): you are absolutely a provision made for me 
from Above. Wendme, I will not forget the first incident on the bybanen. Sabiye, 
your tight schedule and a busy family life did not stop you from doing so much good 
for me. I will not forget the delicious meals you cooked and the lunch boxes you 
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packed for me. My Father shall supply to your needs for the loving-kindness you 
have shown to me all these years.  
Samson Hussein and Dani: thank you for the friendship and great times in Bergen.  
Members of Agape Church in Bergen, for the fellowship and the love you showed to 
me. 
Hagos Zeferu (JZ): this is the result of the “Mega treaty”—it all started there. Thank 
you so much for serving as a source of courage to make brave decisions. 
The data collection for this work would have not been possible without the 
collaboration and strong commitment of the study participants and their families, 
hospital managers, Ato. Abebe Bekele, Ato.Kassahun Amenu, and the data collectors.  
Misge and Eyu, thank you so much for your assistance with the editorial work. 
My mum and dad (Mekdes Tilahun and Taddesse Tolla): with this PhD journey, I 
learned that one (I) can never grow old for her/his (my) parents. Thank you so much 
for all the love and encouragement you provided me persistently! I love you both.  
My spiritual father (Apostle Zelalem Getachew), Mamaye (Prophetess Yodit 
Tesfaye), and women of God—pastor Eleni, Asrat, Zenash, and Abebech—thank you 
for holding my hands up with your prayers.  
Sibblings (Ketsebaot Taddesse, Misgana Taddesse, Yitbarek Getahun, Rommel 
Taddesse, and Bethel Taddesse), Genet Tilahun, and Daniel Tilahun, and the rest of 
my family—thank you for supporting in every way you can.   
Rahel Assaye: for the blessing that you are. My Kanuna (Hasset Solomon): for the 
sweet and cute distraction that you were during the past two years.  
Marlo and Solye: for the sustained provision of the supplies you packed for me 
during my travels to Bergen.  
Fikadu Tilahun: for being a caring brother during these three years. 
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Getahun Tilahun: for taking care of the administrative issues at home when I am 
away.  
Haimanot Tolla: for e-introducing me with Joyce Meyer, who was a great 
“companion” in this journey. 
Dr. Dawit Desalegn: for providing me with office space at the Center for Medical 
Ethics and Priority Setting in Black Lion hospital. 
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Abstracts (English, Amharic, and Norwegian) 
English summary 
Introduction: The burden from cardiovascular disease (CVD) and its risk factors is 
growing in Ethiopia, especially in urban areas. Yet, the coverage of effective 
strategies towards its successful control is low. In the absence of universal coverage, 
affected households are forced to cover the cost of needed health care through direct 
out-of-pocket (OOP) payments upon use of services. OOP payments could be 
prohibitive to health care access and often entail trading-off other essential 
consumptions, especially among the poor. Therefore, protecting households from 
such unprecedented financial consequences is one of the key health systems 
objectives. Nevertheless, Ethiopia is faced with extreme resource scarcity. Therefore, 
priorities need to be carefully evaluated and systematically identified among 
competing alternatives. This thesis aims to generate policy-relevant evidence on 
health outcomes, costs, and financial risk protection of CVD interventions so as to 
inform priority setting decisions in Ethiopia. 
Methods: To meet these aims, we conducted three studies using distinct methods. 
First, to assess the financial risk related to seeking CVD care, we conducted a cross-
sectional cohort study among individuals who sought prevention and treatment 
services for CVD in selected hospitals in Addis Ababa, Ethiopia. In study II, a cost-
effectiveness analysis (CEA) of a broad range of prevention and treatment services 
for CVD was performed in an Ethiopian setting so as to identify cost-effective 
alternatives for a potential scale-up in Ethiopia. In study III, extended cost-
effectiveness analysis was used to estimate the distribution (across income quintiles) 
of health benefits (disability-adjusted life years (DALYs) averted) and financial risk 
protection (cases of catastrophic health expenditure averted (CHE)) from universal 
public finance (UPF) of primary prevention of CVD with a multidrug therapy 
(aspirin, antihypertensives, and statins) for individuals with increased absolute risk of 
CVD. CHE is here defined as annual OOP expenditure on CVD care 10% or more of 
households’ annual income. 
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Results: Overall, 27% [95% CI (23.1, 30.6)] of the households faced CHE. About 
28% among the poorest quintile, in contrast to 14% among the richest quintile faced 
CHE. This financial risk affected mainly the poor, those who have had stroke, those 
who have been hospitalized, and those who travelled to Addis Ababa from outside the 
city to seek CVD care. Moreover, the households that faced CHE among the poorest 
quintile spent 34% of their annual income on CVD care per year compared with a 
15% average among the richest quintile. This shows that the poorest households 
suffered a more severe intensity of financial risk among than the richest quintile. 
We found that primary prevention of CVD with the multidrug therapy is cost-
effective in an Ethiopian setting with an estimated cost of US$ 67 per DALY averted 
at > 35% absolute risk of developing a CVD event over the next 10 years. The 
incremental cost per an additional DALY averted increased moderately at lower risk 
levels and reached US$ 340 per DALY averted at > 5% risk level. A package of 
aspirin, ACE-inhibitor, beta-blocker, and streptokinase for acute myocardial 
infarction (with an estimated cost of US$ 1,000 per DALY averted); a package of 
aspirin, ACE-inhibitor, beta-blocker, and statin for secondary prevention of ischemic 
heart disease (with an estimated cost of US$ 1,850 per DALY averted); and a 
package of aspirin, ACE-inhibitor and statin for secondary prevention of stroke (with 
an estimated cost of US$ 1,060 per DALY averted), although they dominated the 
comparators within their respective clusters, they were deemed less cost-effective 
than primary prevention.  
Furthermore, we estimated that substantial health and financial risk protection gains 
can be expected from UPF of the multidrug therapy for primary prevention of CVD. 
In total, the policy averted about 5,800 DALYs and 850 cases of CHE per year at an 
estimated annual cost of US$ 1.9 million. Disaggregated by risk level, the DALYs 
averted ranged from 1,180 (at > 25%) to 2,240 (at > 15%), whereas the cases of CHE 
averted ranged from 96 (at > 35%) to 394 (at > 5%). The DALYs averted were 
distributed across income quintiles (Q1—the poorest to Q5—the richest) as: 22% 
(Q1), 18% (Q2), 24% (Q3), 26% (Q4), and 10% (Q5); while CHE averted were 
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distributed as: 23% (Q1), 20% (Q2), 21% (Q3), 23% (Q4), and 13% (Q5). These 
distributional patterns were maintained at all CVD risk levels. 
Conclusions: Seeking prevention and treatment of CVD represents a significant 
financial risk to households, with a disproportionate impact on the poorest, those who 
have had stroke, and those who reside outside Addis Ababa. Primary prevention of 
CVD with multidrug therapy to individuals with increased absolute risk of CVD is a 
cost-effective strategy that Ethiopia could consider for successful control of CVD. 
Public finance of this intervention would generate a sizeable financial risk protection 
gains in addition to the health benefits. Both the health gain and financial risk 
protection gains favor the poorer households—qualifying the strategy as a pro-poor 
with respect to both outcomes. Primary prevention of cardiovascular disease saves 
more than lives in Ethiopia. 
 
Keywords: cost-effectiveness, extended cost-effectiveness analysis, financial risk 
protection, equity, poverty, Ethiopia, cardiovascular disease, prevention, treatment.
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Amharic summary 
መግቢያ: የ ልብ ስትሮክ እና ተያያዥ በሽታዎች በኢትዮጲያ በተለይም በከተሞች አካባቢ እየጨመረ 
ይገ ኛል ሆኖም በሽታውን ለመቆጣጠር የ ሚያስችሉ የ ጤና አገ ልግሎቶች ሽፋን አናሳ ነ ው፡ ፡  የ ጤና መድህን 
ሽፋን በበቂ ሁኔታ በማይኖርበት ጊዜ በበሽታው የ ተጎ ዱ ቤተሰቦች አስፈላጊውን የ ጤና አገ ልግሎት 
ለማግኘት ከራሳቸው ኪስ በቀጥታ ለመክፈል ይገ ደዳሉ፡ ፡  እንዲህ ያሉ ከጤና አገ ልግሎት ጋር የ ተያያዙ 
ቀጥተኛ ወጪዎች ደግሞ በአንድ በኩል ህብረተሰቡ አጥጋቢ በሆነ  መልኩ የ ጤና አገ ልግሎት እንዳያገ ኝ 
እክል ሲፈጥሩ በሌላ በኩል ደግሞ ቤተሰቦችን ለድህነ ት አዘቅት አደጋ ያጋልጧቸዋል፡ ፡  ስለዚህም 
ቤተሰቦች የ ሚያስፈልጋቸውን የ ጤና አገ ልግሎት ለማግኘት ከሚያወጡት ቀጥተኛ ወጪ ጋር ተያይዞ 
ከሚመጣባቸው ኢኮኖሚያዊ አደጋ መጠበቅ የ ጤና ስርዓቶች ዋነ ኛ አላማዎች አንዱ ነ ው፡ ፡  ሆኖም ኢትዮጲያ 
ከፍተኛ የ ፋይናንስ እጥረት አለባት፡ ፡  ስለሆነ ም ቅድሚያ አግኝተው ሽፋን ሊሰጣቸው የ ሚገ ቡ የ ጤና 
አገ ልግሎቶችን ለይቶ ማወቅ ይገ ባል፡ ፡  የ ዚህ ጥናት አላማ የ ልብ ስትሮክ እና ተያያዥ በሽታዎቸን 
ለመቆጣጠር የ ሚያስፈልጉ የ ጤና አገ ልግሎቶች ለቤተሰቦች የ ሚያስገ ኙትን ጥቅም ከጤና እና ከኢኮኖሚያዊ 
የ መድን ዋስትና አንፃ ር እንዲሁም አስፈላጊ ወጪዎችን በተመለከተ የ ጤና ፖሊሲ ለመቅረፅ ግብዓት 
የ ሚሆኑ መረጃዎችን ማውጣት ነ ው፡ ፡  
ዘዴዎች:እነ ዚህን አላማዎች ለማሳካት ልዩ ልዩ ዘዴዎችን በመጠቀም ሶስት ጥናቶችን ተግባራዊ 
አድርገ ናል፡ ፡  በመጀመሪያው ጥናት  ለተጠቀሱት ለልብ እና ተያያዥ በሽታዎች የ ጤና አገ ልግሎት 
ለማግኘት በሚደረጉ ቀጥተኛ የ ኪስ ወጪዎች በቤተሰቦች ላይ የ ሚያስከትሉትን ኢኮኖሚያዊ ስጋቶች 
ለመገ ምገ ም በኢትዮጲያ ዋና ከተማ በአዲስ አበባ በሚገ ኙ ሆስፒታሎች ውስጥ አገ ልግሎቱን ለማግኘት 
በመጡ ግለሰቦች ላይ ነ ው፡ ፡  ሁለተኛው ጥናት ደግሞ በኢትዮጲያ እነ ዚህን በሽታዎች ለመቆጣጠር 
የ ሚያስችሉ አዋጪ የ ጤና አገ ልግሎቶችን ለመለየ ት የ ተደረገ  ጥናት ሲሆን በሶስተኛው ጥናት ደግሞ 
በሁለተኛው ጥናት አዋጪ ሆኖ የ ተገ ኘውን የ ጤና አገ ልግሎት የ ኢትዮጲያ መንግስት ሙሉ በሙሉ ቀጥተኛ 
ወጪውን ቢሸፍን ለቤተሰቦች የ ሚያስገ ኘው ጥቅም ከጤና (በዳሊ አቨርትድ) እና ከኢኮኖሚያዊ የ መድን 
ዋስትና (በካታስትሮፊክ የ ጤና ወጪዎች አቨርትድ) አንፃ ር እንዲሁም አስፈላጊ ወጪዎችን ግምት 
መገ ምገ ም ነ ው፡ ፡    
ካታስትሮፊክ የ ጤና ወጪ ብለን የ ምንጠራው አንድ ቤተሰብ በዓመት ውስጥ ለልብ እና ተያያዥ በሽታዎች 
አገ ልግሎት ለማግኘት ቀጥተኛ የ ኪስ ወጪ ከአጠቃላይ የ ቤተሰቡ አመታዊ ገ ቢ አስር በመቶ እና ከዚያ 
በላይ የ ሚሆን ከሆነ  ነ ው፡ ፡  
ዳሊ መድሀኒቶቹ የ ሚያስገ ኙትን የ ጤና ጥቅም ለመለካት የ ተጠቀምነ ው መለኪያ ሲሆን በሽታዎች 
የ ሚያስከትሉትን ሞትና አካል ጉዳት ያካተተ የ ጤና ደረጃ መለኪያ ነ ው፡ ፡  
ውጤት:በአጠቃላይ ከ27 በመቶ የ ሚሆኑ ቤተሰቦች (27% [23.1, 30.6]) ለካታስትሮፊክ የ ጤና 
ወጪ የ ተዳረጉ ሲሆን ይህ ችግር በተለይም በዝቅተኛ የ ኑሮ ደረጃ ላይ በሚገ ኙ ቤተሰቦች ላይ ጎ ልቶ 
 13 
የ ሚታይ ነ ው፡ ፡  እንደ ኢኮኖሚያዊ ደረጃቸው ቤተሰቦችን በአምስት ብንከፍላቸው በጣም ደሀ ከሆኑት 
የ መጀመሪያዎቹ 20 በመቶ መሀል 28 በመቶ የ ሚሆኑት ካታስትሮፊክ የ ጤና ወጪ ሲያጋጥማቸው በአንፃ ሩ 
ደግሞ በጣም ሀብታም ከሆኑት 20 በመቶዎቹ ደግሞ 14 በመቶ የ ሚሆኑት ለተመሳሳይ ኢኮኖሚያዊ ቀውስ 
ተዳርገ ዋል፡ ፡  ይህ ኢኮኖሚያዊ ችግር በተለይም በዝቅተኞቹ 20 በመቶዎች ላይ እንዲሁም በስትሮክ 
በሽታ በተጋለጡ ላይ እና የ ጤና አገ ልግሎቱን ለማግኘት ከተለያዩ ከተሞች ወደ አዲስ አበባ በመጡ 
ቤተሰቦች ላይ ነ ው፡ ፡  በተጨማሪም በጣም ደሀ የ ሆኑት (የ መጀመሪያው 20 በመቶ) ቤተሰቦች በአማካኝ 
34 በመቶ የ ቤተሰቡ አመታዊ ገ ቢ ቀጥተኛ የ ኪስ ወጪ ሲጋለጡ በአንፃ ሩ ደግሞ በጣም ሀብታም የ ሆኑት 
(አምስተኛው 20 በመቶ) ለ15 በመቶ ወጪ ተጋልጠዋል፡ ፡ ይህ የ ሚያመለክተው ከልብ እና ተያያዥ 
በሽታዎች ጋር በተያያዘ ደሀ ቤተሰቦች ከፍተኛ ለሆነ  ኢኮኖሚያዊ አደጋ እንደሚጋለጡ ነ ው፡ ፡   
በተጨማሪም በ10 አመታት ውስጥ ከ35 በመቶ በላይ የ ልብ በሽታ ለመከሰት አደጋ ያላቸው ግለሰቦች 
ላይ ያተኮረ የ ቅድመ መከላከል ጥቅል ህክምና (አስፕሪን፣  ኤሲኢ ኢንሂቢተር፣  ቤታ፣  ብሎከር እና 
ስታቲን) በአመት $67 በዳሊ አቨርትድ ይፈጃል፡ ፡  ይህ የ ቅድመ መከላከል ጥቅል መድሀኒት ከ 5 
በመቶ በላይ አደጋ ላላቸው ግለሰቦች ቢሰጥ በአማካኝ $340 በ ዳሊ አቨርትድ ይፈጃል፡ ፡  ይህ 
የ ሚያሳየ ው የ ቅድመ መከላከል ጥቅል ህክምና ዋጋ የ ግለሰቦቹ አደጋ ተጋላጭነ ት ሲቀንስ በመጠኑ 
ይጨምራል፡ ፡   በተጨማሪም አስፕሪን ፣  ኤሲኢ ኢንሂቢተር፣  ቤታ ብሎከር እና እስትሪፕቶካይኒዝ 
ለአስቸኳይ የ ልብ ድካም ህክምና $1000 በዳሊ አቨርትድ ሲፈጅ ፤  ዳግም የ ልብ በሽታ መከላከል 
ጥቅል (አስፕሪን ኤሲኢ ኢንሂቢተር፣  ቤታ ብሎከር እና ስታቲን) $1850 በዳሊ አቨርትድ 
ይፈጃል፡ ፡ በተጨማሪም ዳግም ስትሮክን ለመከላከል (አስፕሪን ፣  ኤሲኢ ኢንሂቢተር እና ስታቲን)  
$1060 በዳሊ አቨርትድ ይፈጃል፡ ፡ በመሆኑም እነ ዚህ መድሀኒቶች ከለሎቹ አስቸኳይ ህክምናና ዳግም 
ህክምና አንፃ ር የ ተሻሉ ቢሆኑም ከቅድመ መከላከል ህክምና አንፃ ር አዋጪ አይደሉም፡ ፡   
እንዲሁም መንግስት አዋጪ የ ሆነ ውን የ ቅድመ መከላከል ጥቅል ህክምና (አስፕሪን ፣  ኤሲኢ ኢንሂቢተር፣  
ቤታ ብሎከር እና ስታቲን) ሙሉ በሙሉ የ ቀጥተኛ ወጪውን ከ20 በመቶ ለሚሆኑ ለአደጋው ተጋላጭ 
ግለሰቦች ሽፋን ፖሊሲ ተግባራዊ ቢያደርግ በአጠቃላይ 5800 ዳሊዎች እንዲሁም 850 የ ሚያህሉ 
የ ካታስትሮፊክ የ ጤና ወጪዎችን መግታት ይቻላል፡ ፡  ይህም ፖሊሲ በአመት $1.9 ሚሊዮን አሜሪካን 
ዶላር የ ሚሆን ወጪ መንግስት ላይ ያስከትላል፡ ፡  እንደ የ ልብ በሽታ መከሰት አደጋ ተጋላጭነ ት 
ደረጃቸው ተጠቂ ግለሰቦችን ብንከፋፍል ደግሞ 25% አደጋ ባላቸው ላይ 1180 ዳሊ አቨርትድ እስከ 
15% አደጋ ባላቸው ላይ 2240 ዳሊ አቨርትድ ይደርሳሉ፡ ፡  እንዲሁም ከ35% በላይ የ ልብ በሽታ 
መከሰት አደጋ ባላቸው ቤተሰቦች ላይ 96 ካታስትሮፊክ የ ጤና ወጪዎች እስከ ከ5% በላይ  የ ልብ 
በሽታ መከሰት አደጋ ባላቸው ቤተሰቦች ላይ ደግሞ 394 ይደርሳሉ፡ ፡ የ ተገ ቱት ዳሊዎች ክፍፍል ደግሞ 
22% (የ መጀመሪያ 20 በመቶዎቹን) ተጠቃሚ ሲያደርጋቸው 18%  (ሁለተኛ 20 በመቶ)፣  24% 
(ሶስተኛ 20 በመቶ)፣  26%  (አራተኛ 20 በመቶ) እና 10%  (አምስተኛ 20 በመቶዎቹን) 
ተጠቃሚ አድርጓል፡ ፡  በተመሳሳይ በፖሊሲው የ ተገ ቱት የ ካታስትሮፊክ የ ጤና ወጪዎች 23% (በመጀመሪያ 
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20 በመቶ)፣  20% (ሁለተኛ 20 በመቶ)፣  21% (ሶስተኛ 20 በመቶ)፣  23%  (አራተኛ 20 
በመቶ)  እንዲሁም የ ተቀረው 13%  (አምስተኛ 20 በመቶ) ተጠቃሚ አድርጓል፡ ፡   
ማጠቃለያ 
የ ልብ እና ተያያዥ በሽታዎችን ለመከላከል እና ለመቆጣጠር የ ሚያስፈልጉ የ ጤና አገ ልግሎቶችን ለማግኘት 
የ ሚደረጉ ቀጥተኛ የ ኪስ ወጪዎች በቤተሰቦች ላይ ከፍተኛ ኢኮኖሚያዊ ጫና የ ሚያሳድሩ ሲሆን ይህም 
ተፅ ዕኖ በተለይም በኑሮ ደረጃቸው ዝቅተኛ የ ሆኑ ቤተሰቦችን በስትሮክ የ ተጎ ዱ ቤተሰቦችን እንዲሁም 
ከአዲስ አበባ ውጪ የ ሚኖሩ ቤተሰቦችን በተለየ  መልኩ ተጎ ጂ ያደረገ  ነ ው፡ ፡  የ ዚህ በሽታ ቅድመ 
መከላከያ ጥቅል አገ ልግሎት ለአደጋው ተጋላጭ ለሆኑ ግለሰቦች ቢሰጥ አዋጪ ሲሆን  መንግስት ይህንን 
ህክምና አገ ልግሎት ሽፋን ቢያደርግ ጉልህ የ ሚባል የ ጤና እና ኢኮኖሚያዊ ጥቅሞች ለቤተሰቦች 
የ ሚያስገ ኝ ነ ው፡ ፡  በተጨማሪም የ ሚገ ኙት የ ጤና እና ኢኮኖሚያዊ ጥቅሞች በተለይም ደሀ ቤተሰቦችን 
ተጠቃሚ ስለሚያደርጉ ይህ የ ቅድመ መከላከያ ጥቅል ህክምና አገ ልግሎት  ድሆችን ያማከለ ተብሎ ሊፈረጅ 















Introduksjon: Sykdomsbyrden fra hjerte- og kar lidelser (CVD) øker i Etiopia, 
spesielt i byområder. Det er også en økning i forekomst av CVD risikofaktorer. 
Dekningen av effektiv behandling og forebygging er ekstremt lav. I mangel på 
helsehjelp, er de berørte pasientene og familiene tvunget til å dekke kostnadene for 
behandling og forebygging ved direkte egenbetaling. Disse kostnadene kan være 
svært høye og katastrofale, særlig for de fattige. Derfor er beskyttelse fra slike 
uforutsette helseutgifter en av de viktigste målene til helsevesenet. I tillegg står 
Etiopia overfor ekstrem ressursskarphet. Derfor er det viktig å systematisk 
identifisere konkurrerende alternative helsetjenester og prioritere de mest 
kostnadseffektive tjenestene som også vektlegger rettferdig fordeling og finansiell 
risikobeskyttelse. Denne oppgaven tar sikte på å generere policy relevant evidens på 
helseutfall, kostnader og finansiell risikobeskyttelse av CVD-intervensjoner for å 
informere prioriteringsbeslutninger i Etiopia. 
Metode: For å nå disse målene har vi gjennomført tre studier med tre ulike metoder. 
For det første, for å vurdere den eksisterende økonomiske risikoen knyttet til å søke 
CVD-omsorg, gjennomførte vi en tverrsnittstudie blant personer som søkte 
forebygging og behandling for CVD på utvalgte sykehus i Addis Ababa, Etiopia. I 
studie II gjorde vi en helseøkonomisk evaluering av flere ulike typer forebygging og 
behandling for hjerteinfarkt og slag i et etiopisk helsevesen for å identifisere de mest 
kostnadseffektive alternativene for en potensiell oppskalering i Etiopia. I studie III 
utvidet vi den helseøkonomiske evalueringen for å estimere den forventede 
fordelingen (mellom inntektsgrupper) av helsegevinsten (sykdomsjusterte leveår 
(DALYs) unngått) og finansiell risikobeskyttelse (tilfeller av katastrofale 
helseutgifter avverget ved hjelp av universell offentlig finansiering av primær 
forebygging av CVD med tre ulike medikament (aspirin, antihypertensiva og statiner) 
for personer med økt absolutt risiko for CVD. Katastrofale helseutgifter er definert 
som at de årlige egenbetalingene til CVD omsorg overstiger 10% av husholdningenes 
årlige inntekt. 
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Resultat: Samlet sett hadde 27% [95% CI (23,1, 30,6)] av husstandene katastrofale 
helseutgifter. Om lag 28% blant den fattigste kvintilen, i motsetning til 14% blant den 
rikeste kvintilen, opplevde katastrofale helseutgifter. Denne økonomiske risikoen 
påvirket i hovedsak de fattige, de som har hatt slag, og de som reiste til Addis Ababa 
fra utenfor byen for å søke CVD-omsorg. Videre brukte husholdningene blant den 
fattigste kvintilene som opplevde katastrofale helseutgifter 24% av sin årlige inntekt 
på CVD omsorg per år sammenlignet med et gjennomsnitt på 5% blant de rikeste 
kvintilene. Dette viser en mer alvorlig intensitet av finansiell risiko blant de fattigste 
kvintilene sammenlignet med de rikeste. 
Vi fant at primær forebygging av CVD er et kostnadseffektivt tiltak i en etiopisk 
kontekst med en estimert kostnad på USD 67 per DALY unngått ved >35% absolutt 
risiko for å utvikle en CVD-hendelse de neste 10 årene. Inkrementell kostnad-nytte 
rate økte moderat ved de lavere risikonivåene og nådde USD 340 per DALY unngått 
på > 5% risikonivået. En pakke med acetylsalisylsyre, ACE-hemmer, beta-blokkere 
og streptokinase for akutt hjerteinfarkt (med en estimert kostnad på USD 1.000 per 
DALY unngått); en pakke med acetylsalisylsyre, ACE-hemmer, beta-blokkere og 
statiner for sekundær forebygging av iskemisk hjertesykdom (med en estimert 
kostnad på USD 1,850 per DALY unngått); og en pakke med acetylsalisylsyre, ACE-
hemmer og statiner for sekundær forebygging av slag (med en estimert kostnad på 
USD 1 060 per DALY avverget), selv om de dominerte komparatorene i sine 
respektive klynger, ble de ansett for å være mindre kostnadseffektive enn 
primærforebygging. 
Videre anslår vi at det kan forventes betydelige gevinster i form av forbedret helse og 
finansiell risikobeskyttelse fra universell offentlig finansiering av de de tre 
medikamentene som primær forebygging av hjerte-kar lidelser. Samlet sett hindret 
primærforebygging ca. 5.800 DALY og 850 tilfeller av katastrofale helseutgifter per 
år til en estimert årlig kostnad på USD 1,9 millioner. Disaggregert i forhold til 
risikonivået, varierte DALY gevinstene fra 1,180 (ved> 25 %) til 2,240 (ved> 15%), 
mens katastrofale helseutgifttilfellene avverget varierte fra 96 (ved> 35%) til 394 
(ved> 5%). DALY unngått ble fordelt relativt over inntektskvintilene (Q1-de fattigste 
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til Q5-de rikeste) som: 22% (Q1), 18% (Q2), 24% (Q3), 26% (Q4) og 10% ); mens 
katastrofale helseutgifter avverget ble fordelt som 23% (Q1), 20% (Q2), 21% (Q3), 
23% (Q4) og 13% (Q5). Dette distribusjonsmønsteret ble opprettholdt på alle hjerte-
kar risikonivåer. 
Konklusjon: Å oppsøke forebygging og behandling av hjerte-kar lidelser 
representerer en betydelig finansiell risiko for husholdninger, med en 
uforholdsmessig påvirkning på de aller fattigste, de som har hatt slag, og de som bor 
utenfor Addis Ababa. Primær forebygging av hjerte-kar lidelser med til personer med 
forhøyet absolutt risiko for en kardiovaskulær hendelse er en kostnadseffektiv strategi 
som Etiopia bør vurdere for å lykkes med å kontrollere hjerte-kar lidelser nå og i 
fremtiden. Offentlig finansiering av dette tiltaket vil gi store finansiell 
risikobeskyttelse i tillegg til helsemessige fordeler. Både helsegevinsten og den 
finansielle risikobeskyttelsen favoriserer de fattigste husholdningene – som gjør at 
strategien kvalifiserer som pro-fattig med hensyn til begge utfall. Primær forebygging 
av kardiovaskulær sykdom sparer mer enn liv i Etiopia. 
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1.  Introduction 
Ethiopia is a low-income country with about 100 million people characterized by 
high disease burden and as a result, high demand for health care. The burden of 
cardiovascular disease and its risk factors is rising, especially in urban areas. This 
development constrains the already strained Ethiopian health system. Besides, since 
Ethiopia lacks universal health coverage, the effect extends to households in the form 
of financial distress and lack of access to health care. Therefore, there is an acute 
need for evidence to inform priority setting decisions to allocate public funds among 
several competing alternatives. In this thesis, I intend to generate evidence to 
facilitate better informed resource allocation decisions, specifically addressing three 
main policy relevant questions focusing on cardiovascular disease, as an entry point 
to this crucial endeavor. The first question was: is seeking CVD services a financial 
risk to households in Ethiopia? If so, who are affected the most? Or what are the 
factors associated with it? The second question was, are there cost-effective 
prevention and treatment strategies for CVD that Ethiopia could consider for a 
potential scale-up? Finally, I examined the expected costs, gains (in terms of health 
and financial risk protection (FRP) benefits), and the expected distributional 
consequences of public finance of the most cost-effective strategy that we identified 
when addressing the second question.  
This thesis is organized in eight sections. Section 1 introduces the topics of this 
thesis: universal health coverage (section 1.1), priority setting for health care (section 
1.2), Ethiopian context (section 1.3) that covers the health system context and 
epidemiology of CVD in Ethiopia—among others, and justification of the study 
(section 1.4). Study objectives are presented in section 2, while section 3 describes 
the study setting (section 3.1), discussion of the methodological considerations 
(section 3.2, where I discuss the rationale behind the choice of analytical approaches 
and outcome measures), and a summary of the specific methods employed in each 
paper (section 3.3). The results section follows in section 4, providing a summary of 
the key findings from the three studies that we conducted and in section 5, I discuss 
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these results in view of the secondary objectives and existing literature (section 5.2) 
and highlighted the main methodological strengths and limitations (section 5.3). 
Finally, key conclusions from the study are presented in section 6, followed by 
implications for future practice (section 7.1) and recommendations for future research 
(section 7.2), and the last section (section 8) offers the references I used.  
1.1 Universal Health Coverage 
UHC is defined as all people receiving quality health services that meet their needs 
without being exposed to financial hardship in paying for the services (1, 2). It covers 
promotive, preventive, curative, and rehabilitation services that respond to the needs 
of populations. Given its prominent role to development, UHC is set as one of the key 
sub-targets of the Sustainable Development Goal 3 (3). The motivation behind 
pursuing UHC finds its main root at the society’s moral obligation to protect its 
members against the consequences of poor health in all its forms. This relates to a 
large extent to the inherent value of health for one’s well-being and consequently its 
role in determining individuals’ fate of reaching maximum potential in life, their 
livelihood, and enjoyment in life (4). An equally appealing pro-UHC cause, however, 
is the enormous economic dividend that follows investments on health (5). It is 
estimated that a 10% increase in life expectancy translates to an economic growth of 
0.4% per year of a country’s gross domestic product (GDP) (6). The Lancet 
Commission Global Health 2035 estimated that nearly 24% of the increase in full 
income in low-and middle-income countries, between 2000 and 2011, was the 
consequence of reductions in mortality, improvements in health, and enhanced 
economic productivity (5). The commission also forecasted that per $ invested, health 
services could generate a 9-20 fold higher economic return—positioning UHC as an 
essential prerequisite for a sound social and economic development (5, 7).  
Commitment to UHC implies making continual progress on three fronts: expanding 
the package of essential health services covered, scale-up coverage of beneficiaries, 
and increasingly raise the share of health care costs financed through pooled pre-
payment arrangements (1, 2). Nevertheless, the progress towards UHC is faced with 
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steeply increasing health care costs related to continued advancements in health care 
technologies, changing demography and epidemiologic patterns resulting in change in 
health needs, and rising public expectations (8). Therefore, countries are required to 
carefully define a comprehensive package of essential services that they can 
effectively deliver within their local constraints. Among other things, these 
constraints include resource scarcity, other social goals such as improving access to 
education or roads, adequacy of available health service delivery infrastructure, 
human resources for health, and the political economy (9-11). Consequently, 
countries face a perpetual challenge of defining the best route to move toward the 
UHC goal, in particular: which services to cover first, whom to cover first, and how 
to switch from out-of-pocket (OOP) payments to prepayment mechanisms (12). 
In 2005, Ethiopia identified a prioritized Essential Health Services Package (EHSP) 
that the country can afford to offer to its citizens at the primary health care level (13). 
The services offered include a list of promotive, preventive, basic curative, and 
rehabilitation services that target major causes of disease burden that are subject to 
three distinct cost-sharing arrangements based on the level of priority. First, exempted 
services are those that are provided free of charge (no cost sharing) to all and 
typically constitute immunization, TB, HIV, family planning, and child delivery at 
primary health care facilities. The second group constitutes the services that are 
offered on a cost-sharing basis that individuals have to pay directly to providers upon 
use of the services (13). The subsidy could reach 60-70% for some services (14). 
These include curative services for common infectious diseases and selected primary 
prevention interventions for some NCDs such as hypertension and diabetes mellitus 
(14). The third group constitutes services that are delivered on a high (full) cost 
recovery basis, and include all services that are not in the prioritized package (13). 
Based on the EHSP, it seems that primary prevention of CVD falls under the second 
group (subsidized service), while treatment of acute conditions and secondary 
prevention seem to fall under the third payment arrangement (high or full cost 
recovery). Health insurance coverage is still very low in Ethiopia—although it 
increased from 1% in 2011 to 7% in 2016 (15, 16). Additionally, with the main aim 
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of enhancing equitable access to health care, the fee-waiver scheme reached out to 
nearly 1.5 million poor individuals (about 1.5% of total population) with free access 
to health care of all kinds—with an estimated annual average spending of less than 
US$ 2 per capita in 2015/2016 (17). Although encouraging, this is far from meeting 
the high demand for health care in Ethiopia.  
Nevertheless, UHC is not an unpredictable journey to a promised land even in 
resource-limited settings. With the right-mix of policy choices and unwavering 
commitment, countries such as Rwanda, Ghana, and Thailand have demonstrated that 
a remarkable progress can be made towards UHC even in low- and middle-income 
settings (1). Countries are free to define pathways that better suit their local context 
(1, 18). However, there are broadly accepted guiding ethical principles that countries 
ought to comply with to accelerate progress towards UHC in a fair manner (2). At 
any given level of available resources, it is a “moral imperative” (19) to maximize the 
total health benefits for the whole population while ensuring a fair distribution of the 
benefits between sub-populations—especially the poor (2, 20, 21). In so doing, 
countries need to protect citizens from an unacceptable financial risk households face 
due to illness in general, but at least due to payments for needed health care (2, 22). 
These are key principles and are further discussed in subsequent sections. 
1.2 Priority setting for health care  
In as much as the global community is convinced about the importance of pursuing 
UHC, the prevailing resource scarcity proves an important rate-limiting factor 
towards achieving that goal (23). Countries cannot cater to all health needs of their 
populations in the face of immense resource scarcity, growing demand for health 
care, and ever improving health technology development (24). In such situations, 
decision makers are forced to take the tough job of choosing between alternative 
services for prioritized financing (25). Needless to say, it is not an easy task to make 
those trade-offs, since such decisions may mean denying potentially beneficial 
interventions for some who could have benefited from the same resources (8, 25, 26). 
Typically, priority setting decisions are taken by “agents” on behalf of others and the 
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consequences of their decisions might equate allowing some to enjoy a better quality 
or longer life at the expense of others who are destined to have less health because the 
available resources are allocated to the needs of others. Hence, systematic priority 
setting becomes not just an unavoidable route, but a pragmatic means to a desired 
end. Ad-hoc approaches to priority setting could leave out important interventions 
that deserve higher priority, may risk leaving behind disadvantaged sub-populations, 
or cause inefficiency—resulting in a huge opportunity cost in healthy life years lost 
(8, 10, 19, 24, 26). Therefore, explicit priority setting grounded on legitimate 
evidence and agreed upon criteria helps to optimize the gains from the available 
resources in a fair manner (8, 10).  
Varying descriptions have been used to define the concept of priority setting for 
health care. In this thesis, I use rank-ordering of health interventions for prioritized 
public financing as the definition of priority setting (24). According to this definition, 
interventions are ranked based on agreed upon set of criteria for a fair priority setting 
so that the available resources can be allocated first to high-ranking interventions 
while setting aside low-ranking ones until sufficient resources become available for 
all. Although many concur this approach broadly, its practical application entails 
critical value judgments and making explicit trade-offs between alternative choices. 
In addition, the priority setting approach has been debated and scrutinized from 
ethical, philosophical and political perspectives (8, 10). Therefore, one needs to 
actively engage all relevant stakeholders including the public to get their buy-in on 
the relevance of the criteria chosen and the decisions made with appropriate 
mechanisms in place to allow incorporation of possible suggested changes as well as 
enforcement mechanisms to follow through agreed proceedings (27).  
Unfortunately, priority setting is not always undertaken in a systematic and explicit 
manner, especially in low-income settings (10, 25, 28, 29). Factors such as historical 
trends in financing, past experience, political interest, and pressure from various 
interest groups such as donors, the private sector, and patient groups could influence 
resource allocation decisions more than the rational principles (10, 28).  
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Given the background discussed so far and in the subsequent health financing section, 
it is obvious that severe resource scarcity remains an ongoing challenge for health 
care financing in Ethiopia. One alternative to deal with this challenge is to increase 
the allocation of funds to health care (30). An equally important and more realistic 
response in the short term, however, is to improve efficiency in the use of existing 
resources (1, 30, 31). In this thesis, I aim to generate policy-relevant evidence to 
inform macro-level priority setting decisions for health care within a “fixed” budget 
constraint that is expected to grow continually as the government intends to revise the 
EHSP. 
Due to its complexity, multiple criteria are deemed necessary and have typically been 
used to guide priority setting for health care (32-34). Examples include disease 
burden, age, need for health care, poverty, equity, and severity of disease—with a 
predominant representation of benefit maximization criteria across settings (8, 10, 32-
36). The ultimate goal is to maximize health and ensure its fair distribution while 
protecting people from financial risk or medical impoverishment (37, 38). A critical 
first step is then to agree on the criteria that should dictate the decision-making 
process. Through careful review of the global experiences, recommendations from 
the literature, and extensive consultation with relevant stakeholders, WHO’s 
Consultative group on equity and UHC proposed three criteria to guide prioritized 
resource allocation decisions on a fair path to UHC. These are: priority to cost-
effective interventions, priority to interventions that generate greater benefits to the 
worse-off, and priority to interventions that promote FRP. I discuss these criteria in 
subsequent sections. 
1.2.1 Priority to intervention that maximize health benefits 
The prime aim of health systems is to improve the health of populations (2). Health 
systems strive to achieve this goal within a given budget limits. Cost-effectiveness 
analysis (CEA) compares the value of the outcome generated by an intervention with 
those that could have been achieved with an alternative use of the same resources (39, 
40). Hence, it helps policy makers to choose interventions that maximize total health 
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benefits for the population within a given budget limit. Cost-effectiveness of 
interventions is judged by their incremental cost-effectiveness ratio (ICER) which is 
given as the ratio of the incremental cost of the intervention to its incremental health 
gain relative to a comparator. The ratio, reported as cost expressed in monetary units 
per health gain (e.g., cost in US$ per disability-adjusted life year (DALY) averted, 
DALY is a health metric that combines the health lost due to premature death and life 
years lived with disability—discussed in the methods section), informs us of how 
much additional cost the intervention under consideration requires for a unit increase 
in health benefits over its comparator. Therefore, the lower the ratio, the more cost-
effective the intervention is (21). To inform priority setting decision, ICERs can be 
used in two ways (30). ICERs can be compared with a certain fixed cost-effectiveness 
threshold signifying the opportunity cost for a unit health gain. I will return to cost-
effectiveness threshold in the discussion section. Alternatively, interventions can be 
ranked in increasing order of their ICERs; followed by selection of interventions 
based on their rank-order for prioritized financing until the available budget is 
exhausted (21). Allocating resources in such a way helps to arrive at a list of 
interventions that maximize health within the available budget. It is often considered 
unethical not aim to achieve the maximum attainable benefit for a given resource (24) 
due to the subsequent huge opportunity cost in life years lost (19). Nevertheless, this 
criterion is not universally favored by all, such as in the US and Germany (24, 41). 
One challenge is that CEA is resource- (skilled manpower) and- data-intensive—for 
which low-income settings like Ethiopia have limited capacity and preparedness (30, 
42). In order to fill this gap, the Disease Control Priorities project (DCP, started in 
1993) and the World Health Organization’s “Choosing Interventions that are Cost-
Effective” (WHO-CHOICE, started in 1998) pioneered cost-effectiveness analysis of 
a wide range of interventions and programs for most regions globally (43-45). The 
WHO-CHOICE (tasked to provide information of cost-effectiveness, costs, and 
strategic planning to policy makers) and the DCP project (an ongoing project tasked 
to systematically assess the cost-effectiveness of interventions that address major 
causes of disease burden and specific service delivery platforms in low-and middle-
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income countries) have laid the foundation for the introduction of CEA 
considerations in resource allocation decisions at the national levels.  
However, direct transferability and applicability of cost-effectiveness analysis results 
from one setting to another is restricted due to several methodological and practical 
constraints (10, 42, 46). Differences in the analytic approach (the perspective for the 
analysis, choice of comparator, target population, diverging ways valuing costs and 
health benefits), uncertainties in input parameters as well as differences in context 
specific factors (such as epidemiology, demography, relative price of inputs, and the 
institutional make-up of health systems) contribute to the limited transferability of 
results from one setting to another (10, 42). Therefore, building a local capacity to 
undertake the needed economic evaluation evidence is urgently needed in low-
income settings to fill the evidence gap in a timely manner so as to facilitate 
evidence-based decision making based on contextualized CEAs (42). 
Furthermore, benefit maximization does not sufficiently address all societal concerns. 
The society also cares about ensuring a fair distribution of the health benefits between 
sub-populations, even at the expense of a certain level of benefits foregone on an 
aggregate level (47). Mostly, the services that are preferred on the basis of the benefit 
maximization principle also address distributional concerns. However, on some 
occasions, adherence to distributional concerns may require extra costs—and hence, 
diverge from the prior principle. Therefore, exclusively relying on the benefit 
maximization principle may not always align with other relevant ethical concerns (2, 
32). Particularly, standard cost-effectiveness analysis lack sensitivity to the 
distributional concerns as it gives equal weight to all benefits regardless of who gains 
them (32). Moreover, FRP considerations are not captured in standard cost-
effectiveness analysis. Therefore, the method needs to be complemented with other 
methods that allow incorporation of relevant distributional concerns as well as 
concerns for FRP. In the next sections I discuss the rationale behind these two criteria 
and how they can be applied into priority setting decisions with emphasis on the 
latter.  
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1.2.2 Priority to interventions that benefit the worse-off   
The priority to the worse-off principle prescribes giving higher priority to services 
that preferentially benefit those worse-off as it would help to narrow the gap in the 
distribution of health benefits across sub-populations. Meaning, a unit of health 
benefit to the worse-off has greater value than the same unit of health among the 
better-off.  
To understand the implication of the principle, one needs to operationalize worse-off-
ness as it may mean different things in different contexts (10). Worse-off-ness can be 
defined in several ways: in terms of need or overall health (e.g. those with lower life 
time health without the intervention, or those having conditions with the lowest 
healthy life expectancy), or alternatively, it may mean those disadvantaged with 
respect to other relevant parameters such as  socio-economic status and geography 
(e.g., the poor and residents in rural areas that often have weak infrastructure 
development entailing poor access to health care, poor health outcomes, or poor 
access to other basic services ) (2, 10, 39, 48). Giving priority to the worse-off often 
has a dual effect—it may improve total health (because of the substantial “catch up” 
health gain among the worse-off) and promotes equalization of health (2). In most 
cases, what is preferred from a benefit maximization perspective is also beneficial to 
those worse-off. However, this may not be universally true, requiring careful 
assessment and incorporation of trade-offs between health maximization and concern 
to the worse-off into the decision equation.  
Several methods have been proposed to incorporate the concern to the worse-off into 
standard economic evaluation methods. To mention some: equity impact analysis 
(disaggregating the impact of alternative courses of action by certain equity-relevant 
variable) (39); equity constraint analysis (assessment of  opportunity cost of equity 
promoting option compared to equity-neutral option, which is estimated as the 
difference in total health between the two alternatives) (49); and equity-weighting 
analysis (a method of applying varying equity weights—reflecting the concern for 
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equity—to health benefits to people that vary with respect to certain equity relevant 
characteristics) (49, 50). However, I will not go into these details in this thesis.  
1.2.3 Priority to interventions that promote financial risk protection 
Out-of-pocket (OOP) payments for health care can be a substantial financial risk to 
households in most low-income settings that lack universal coverage. I will return to 
the problems with direct OOP payments in health care financing section 
subsequently. FRP can defined as protecting households from incurring high medical 
expenses or the risk of impoverishment (51). Alternatively, FRP has been defined as 
“the absence of a risk of financial hardship” (52). The FRP criterion is especially 
relevant in settings where direct OOP payments constitute a major part of the health 
financing mechanism—putting households at an increased risk of medical 
impoverishment and making them unprotected from income loss due to illness (51). 
FRP is considered as one of the core elements of UHC with an intent to reduce the 
burden on households of high OOP payments for health services and it is therefore 
incorporated as part of the global monitoring framework for UHC (53, 54).  
Generally, public finance of health services improves health care access while 
conferring FRP to individuals in multiple ways (2): 1) it protects households from 
high health care expenditures; 2) preventive services can also protect households 
from potential future expenditures by preventing occurrence of diseases (e.g., primary 
prevention of CVD could prevent the occurrence of acute myocardial infarction or 
stroke and hence, saves households from incurring a potentially substantial spending 
on costly acute care for these conditions), and 3) by improving individuals health 
status, it protects households from potential income loss due to lost productivity. 
However, the expected FRP gains from the coverage of health services can vary 
depending on several factors: epidemiology of the condition targeted, health service 
utilization, service availability, the magnitude of OOP payments, and the cost of 
services (2, 5).  
The FRP criterion justifies additional priority to health services that promote high 
FRP even if they are less cost-effective (2, 24).  It is often assumed that public 
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finance of costly services would confer high FRP gains (55). However, in settings 
where OOP payments are present even for basic services, public finance of low-cost 
essential services (hence, very cost-effective) could generate high FRP gains at the 
aggregate level (2, 5, 56-58). Under such conditions, these low-cost services could be 
considered good both from the health and FRP perspectives. The challenge is when 
the service under consideration have different impact with respect the two criteria. I 
use the matrix below (Figure 1) to illustrate the possible performance of services with 
respect to health and FRP (I will further return to this matrix in the discussion 
section). If the service under consideration falls in the “High FRP and low health 
benefits” quadrant and “High health benefits and low FRP” quadrant, trade-offs 
would have to be made—for which there could be reasonable disagreements. In 
addition, the weight of the FRP criteria relative to health is another area amenable for 




Low health benefits 
 
 
                  High FRP 
High health benefits 
 
 





High health benefits 
Low FRP 
 
Figure 1: Cost-effectiveness versus financial risk protection (FRP) matrix for an 
intervention compared to an alternative, reproduced from Verguet et al., (56). 
The next question is how do we explicitly incorporate the concern for FRP into 
economic evaluation of health services to facilitate priority ranking of health 
services? Recently, a methodology called extended cost-effectiveness analysis 
(ECEA) was developed under the auspices of the DCP, 3
rd
 edition (www.dcp-3.org) 
(59). Building on standard CEA, ECEA allows examination of the impact of health 
policies with respect to health and FRP gains (e.g., cases of catastrophic health 
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expenditures (CHE) averted—a measure of financial risk discussed in the methods 
section) as well as the cost to the government of such policies. Therefore, ECEA 
helps policymakers to quantify the efficiency in purchasing FRP by investing public 
funds on alternative health services (56). Furthermore, ECEA quantifies the health 
and FRP gains disaggregated by relevant sub-population groups (e.g., per income 
quintile, or geographical setting)—allowing possible examination of distributional 
concerns (56, 58). In addition, as indicated earlier, when interventions of interest 
perform differentially with respect to the health and FRP perspective—trade-offs may 
arise. The ECEA provides for a quantitative examination of such trade-offs between 
health and FRP. I provide further details about the ECEA approach in the methods 
section of this dissertation. 
A specific framework for incorporating the concern for FRP is the one suggested by 
WHO’s consultative group on equity and a fair path to UHC (2). The commission 
suggested a three-step approach to ranking of services. After identifying all potential 
services that could be considered for public finance: first, one needs to classify the 
services into high, medium, and low priority classes based on relevant cost-
effectiveness thresholds. Subsequently, some services may fall on a clearly 
demarcated priority classes, but some others might fall in an overlapping region 
between two priority classes. This is where the Consultative group suggested to 
introduce the other two criteria, priority to the worse-off and financial risk protection, 
as a differentiation mechanism (2). Services that clearly fall in one category maintain 
their priority class. However, for those services that lie in an over-lapping region, 
further comparison needs to be made based on the priority to the worse-off and FRP 
criteria.  
1.3 Ethiopian context 
1.3.1 Geographic, socio-demographic, and economic background 
Ethiopia is a federal democratic state located in the Horn of Africa. It shares boarders 
with Kenya in the south, Eritrea in the north, Sudan and South Sudan in the west, and 
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Djibouti and Somalia in the east and hence, it is a land-locked country (Figure 2). 
Spread over a land area of 1.1 million square kilometers, it stands as one of the least 
urbanized countries globally, where more than 80% of its population reside in rural 
area (60). The country exhibits a unique terrain with an altitude that ranges from 110 
meters below the sea level in Afar to 4,620 meters above sea level in Ras Dashen 
Mountain. Ancient civilization and glorious history are among the key identities of 
Ethiopia that served a home to human origin and pledges several United Nations 
Educational, Scientific and Cultural Organization World heritage sites including the 
Rock-Hewn Churches of Lalibela and Aksum obelisk (61)  
 
Figure 2: Map of Ethiopia (62). 
The country has the second largest population in Africa, projected at 99.4 million as 
of 2016 (60, 63).The population pyramid is still characterized by a young population, 
with a nearly even male to female ratio (Figure 3). With respect to the age structure: 
40% of the total population is younger than 15 years, while those older than 65 years 
constitute about 3% of the share (63, 64). However, as shown in Figure 3, the 
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Ethiopian population is projected to grow older in the next 30 years (64), which have 
important implications to shifting the epidemiology towards a non-communicable 
disease (NCD) dominated pattern. The total fertility rate declined significantly to 4.6 
in 2016 from 5.5 in 2000 (65), and consequently roughly about 2.3 million children 
are born annually. Ethiopia is a diverse country with more than 80 ethnic tribes 
having different languages and socio-cultural background. Oromo constituted 34.5% 
of the total population, followed by Amhara (26.9%), and Somali (6.2%). Orthodox 
Christian, Islam, and Protestant Christian were the three leading religious 
denominations that 34.5%, 26.9%, and 18.6 % of the population were affiliated with 








Figure 3: Ethiopia population pyramid 2017 and 2050 (64).  
As a federal state, the country follows a decentralized administration system that is 
composed of nine regions, two city administrations, close to 1,000 districts 
(woredas), and about 15,000 kebeles—representing the smallest administrative unit 
under districts and sub-cities (67-69). Power is fully devolved to regional 
governments (states) and city administrations, which in turn empower the district and 
sub-city authorities. The administration at the district and sub-city level is composed 
of elected council members and represents a critical decision making structure in the 
governance system including decision on fiscal allocations to specific sectors (67-69). 
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Due to their autonomy, it is not uncommon to see variation in sectoral allocation 
patterns across regions according to the perceived local priorities. In the health care 
financing section further below, I have provided concrete examples of variation in 
government’s allocation to the health sector across the different regions.  
Ethiopians witnessed tremendous economic and human development gains over the 
past 15 years. The economy registered a steady GDP growth at an average rate of 
about 10% per year since 2004—with a slight deceleration to 9.6% in 2015. As a 
result, the proportion of the poor population (those below the international poverty 
line, purchasing power parity (PPP) $ 1.25) declined to 31% in 2011 from 56% in 
2000 (70). The average life expectancy at birth increased to 64 years in 2015 from 52 
years in 2000 (60). About two-thirds (65%) of Ethiopian school children were 
attending primary school in 2016. Infant mortality and under-five mortality rates were 
reduced by 50 to 60% between 2000 and 2016 to reach 48 and 67 per 1,000 live 
births, respectively (71). In addition, a substantial infrastructure expansion was also 
undertaken during this period. As a result, 65% of Ethiopian households drink water 
from improved sources (includes tap water and protected well or spring), 68% of 
kebeles are connected by all-weather roads and the number of mobile phone 
subscribers reached 28 million in 2014 (69).  
Building on the successes thus far, the country sets an ambitious goal to become a 
middle-income country by 2035. The Growth and Transformation Plan (GTP) II 
(2015/2016 - 2019/2020) directs the remaining journey to the envisioned macro-
economic development (69, 72). Nevertheless, the vision is confronted with real 
challenges demanding unyielding efforts before realization. The gross national 
income (GNI) stood at US$ 590 per capita in 2015 compared to a minimum of US$ 
4,036 baseline for an upper-middle income country (73). The economy is still largely 
dependent on subsistent agriculture that comprised 40% of the GDP in 2015, while 
tax revenue and manufacturing industry constituted 12.7% and 4.4% of the economy, 
respectively (69). In addition, access to basic services such as secondary education, 
electricity, water, sanitation facilities are still far from optimal, which is further 
compounded by wide urban-rural and socio-economic disparity (Table 1). In the next 
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section, I have described the Ethiopian health system context with emphasis on 






















































28 80 21 13 67 97 
Modern 
contraceptive use 
35 45 32 22 46 50 
Ante-natal care 4+ 
visits 
32 63 27 38 77 89 
Pentavalent 3 
vaccine  
53 80 50 38 77 96 
Stunting in under-5 38 25 40 42 27 15 
Some secondary 
education 
6 18 4 2 17 19 
Access to improved 
source of water  
57 65 97    
Access to improved 
toilet facilities 
4 6 16    
Table 1: Distribution of access to basic services in 2016 (in percentages), Ethiopia 
(65). 
1.3.2  Health system context 
The Ethiopian health care delivery system is organized as a three-tier system, firmly 
founded on primary health care (68, 74). The primary health care unit forms the base 
of the health system and it is composed of five health posts, a health center, and a 
primary hospital. Health posts serve as the first contact point to the formal health care 
system for the rural majority in Ethiopia (68, 74). Staffed with two health extension 
workers: health posts serve as the main delivery platform for Ethiopia’s flagship 
health extension program providing preventive, promotive, and very limited curative 
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services to about 3,000 to 5,000 people. Whereas, health centers provide preventive, 
promotive, and curative services including limited inpatient care (five beds) to about 
25,000 people per a health center. Primary hospitals (20 to 50 beds) serve as a referral 
station for lower level units and provide a broader range of curative services 
including emergency surgery. The second-tier is composed of general hospitals that 
serve about one and half a million people. Whereas, tertiary level specialized 
hospitals provide a highly specialized services to nearly five million people on a 
referral basis from lower levels (68).  
The previous 20-year health sector development programs (HSDP I-IV ((1994/1995 
to 2014/2015)) mainly focused on expanding the health infrastructure among other 
things. In 2014, the number of fully functional health facilities reached: about 16,000 
health posts, 3,101 health centers, 27 primary hospitals, 48 general hospitals, and 19 
referral hospitals (75, 76). The public health care delivery system is significantly 
complemented by the private sector—more so for inpatient care. In a nationwide 
survey, 20% of households that sought outpatient care for a reported illness visited 
private facilities whereas 30% of those that sought inpatient care received care from 
private facilities in 2011 (15).  
Moreover, along with the infrastructure expansion, the human resource for health has 
increased both in number and diversity. The number of mid-to-high level health 
cadres in the system has increased exponentially by a factor of 3 to 15 folds. For 
example, between 2005 and 2015, the number of newly graduated medical doctors 
increased from 309 to 948, pharmacists from 70 to 379, midwives from 43 to 548, 
and more than 36,000 health extension workers have been trained and deployed (76, 
77). Led by a strong government commitment, remarkable progress has been made in 
reducing morbidity and mortality from major communicable diseases, childhood and 
maternal conditions, and in improving access to basic health services in Ethiopia. 
Morbidity and mortality from TB, HIV, and malaria were cut by more than half over 
the past decade (17, 78). The health sector transformation plan I (HSTP I) 2015/2016 
- 2019/2020 outlines the sector’s key strategic directions and forms the first part of 
the next 20 years health sector envisioning document and a core element of the GTP-
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II (68). The development process involves a mix of bottom-up and top-down 
approach that engage relevant stakeholders at the national and sub-national level 
including development partners, health professionals, and civil society organizations 
(68). 
In spite of the remarkable progress, Ethiopia still lags behind in ensuring universal 
access to basic health services (71). Only 28% of the deliveries were attained by 
skilled providers; coverage of antenatal care stood at 32% (for four visits); while  
only 53% of eligible children received Pentavalent-3 vaccine in 2016 (71). The low 
coverage of services is compounded by persistent socio-economic and geographic 
disparity (e.g., 50% of children in rural areas received pentavalent-3 compared to 
80% in urban areas and only 22% women in the poorest quintile used modern 
contraceptive methods compared to 46% among the richest group). Furthermore, the 
emerging burden from NCDs presents an ongoing challenge to the sector in the years 
to come. The growing NCD burden and its implication are discussed in the next 
section with emphasis on cardiovascular disease.    
1.3.3 Cardiovascular disease (CVD) in Ethiopia and what is being 
done? 
Worldwide, the total burden from NCDs is rising steadily. In 2013, about 60% of 
total DALYs were attributed to NCDs compared to about 50 % in 2005. Of the 
NCDs, CVD is the leading cause of disease burden. From CVD, ischemic heart 
disease (IHD) and stroke represent the first two major causes of DALYs lost globally. 
In 2015, these two conditions accounted for nearly 80% of all DALYs lost due to 
CVD (79). In terms of mortality, more than 14,000 lives (nearly 27% of all deaths) 
were lost due to the two conditions globally in 2015. Sub-Saharan Africa is one of the 
regions that has seen an increasing NCD burden—a further increase predicted in the 
coming decades with the total DALYs lost from CVD projected at 36% of total 
DALYs by 2030 that increased from 25% in 2010 (80, 81). In 2015, nearly 10% of all 
deaths were attributed to IHD and stroke, although the conditions contribute to 
relatively small share of total DALYs lost in the region (3.4%) (79).   
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CVD is emerging as an important public health challenge to Ethiopia. According to 
the global burden of disease (GBD) study, nearly 15% all deaths in Ethiopia in 2015 
were caused by CVD. IHD and stroke together contributed to 5.4% of total DALYs 
lost and ranked third among the leading causes of disease burden following lower 
respiratory tract diseases and diarrhea in Ethiopia (79). Local studies also affirmed an 
emerging epidemiologic shift towards NCD dominated pattern especially in urban 
areas in Ethiopia (82-85). In Ethiopia’s capital Addis Ababa, Misganaw et al., 
estimated using verbal autopsy methods that about 24% all deaths between 2006 and 
2009 were due to CVD (Figure 4) (86). The same group reported that 11% of all 
hospital deaths in Addis Ababa between 2002 and 2012 were due to CVD (86, 87).  
 
Figure 4: Mortality burden by condition in Addis Ababa between 2006-2009, 
reproduced from Misganaw et al., (86). 
Apart from the health loss, CVD has a multi-dimensional impact on countries’ 
economy (88, 89). In Bloom’s words, the World Economic Forum identified NCDs 
as “one of the leading threats to global economic growth” (90). Observational studies 
revealed that CVD occurs 10 to 15 years earlier in low-income settings as compared 
to high-income settings (6). Hence, CVD may deplete economic systems off 
otherwise productive human capital. Therefore, it greatly compromises countries’ 
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macro-economic potential due to premature loss of life and long-term disability of 
working age adults associated with the disease.  
Moreover, acute IHD and stroke are costly to treat to health systems in low-income 
settings that already suffer from severe resource scarcity and have weak human 
resource and infrastructure capacity. Therefore, the best possible CVD treatment and 
prevention services are not widely available to patients, e.g., percutaneous coronary 
intervention (PCI) for treatment of acute myocardial infarction and long-term 
rehabilitation care for patients who suffered stroke (91, 92).  
At the micro-level, CVD affects household’s economy in several ways (88, 93-96): 1) 
high OOP spending on health care. This is especially relevant in settings like Ethiopia 
that lack UHC. Given its relevance to my research question, I have explained below 
the problems with OOP payments when used as a major source of health care 
financing, 2) lost household income due to loss of life or disability of families’ bread 
winner(s) or change in the work schedule of other family members as a result of the 
sick family members, and 3) it may also lead to compromise on other essential 
consumptions such as food or education—which have potential impact in determining 
one’s future economic potential (88, 93-96).   
Nevertheless, opportunities are available for successful prevention and control of 
CVD. Evidence showed that CVD is to a large extent caused by potentially 
modifiable risk factors; the most common ones being hypertension, high cholesterol, 
and high body mass index (97). According to the 2015 Stepwise approach to NCD 
risk factors surveillance (STEPS) survey, 94% of Ethiopians between the age of 15-
69 years were found to have at least one or more of the well-known risk factors for 
CVD (98). 15.6% had raised blood pressure (having systolic blood pressure of > = 
140 mmHg or diastolic blood pressure of > = 90mmHg). However, 97% of the 
hypertensive individuals were not on treatment. 7.9% were either obese or 
overweight, 5.6% had raised total cholesterol, 4.2% were current smokers, and 
inadequate intake of fruit and vegetables was a nearly universal problem. Most of risk 
factors were more prevalent among urban residents compared to rural (98). Based on 
 44 
these risk factor profile, the Ethiopian Public Health Institute (EPHI) estimated that, 
about 4.7% of adults aged 40-69 years (4.5% in rural and 5.3% in urban) have more 
than 30% risk of developing CVD events over the next 10 years including those with 
established CVD events.  
Generally, CVD and its risk factors disproportionately affect the socioeconomically 
disadvantaged groups. According to the World Health Survey (2003), most CVD risk 
factors were more prevalent among the socio-economically disadvantaged groups. 
Smoking, alcohol intake, inadequate intake of fruits and vegetables, and inadequate 
physical activity were about 1.5 times more prevalent among the poorest quintile 
compared to the richest quintile. In addition, it is well-known that the poorest 
households have poorer access to health care compared to the richest (99, 100). 
With the appropriate measures to address these modifiable risk factors in place, 
Ethiopia can contain the increasing CVD burden. On the one hand, sustained life-
style modification can help prevent a substantial share of the CVD burden (97, 101). 
On the other hand, there are population-wide and individual based primary prevention 
strategies that are of proven effectiveness and cost-effectiveness in many low-income 
settings (92, 102, 103).  
So far, the Ethiopian health sector has paid little attention to NCDs, CVD included 
(78, 91). The coverage of low-cost preventive interventions is low in Ethiopia (85). 
The Ethiopian STEPS survey reported that only 11.5% of individuals with an 
established CVD event or those that have > 30% risk of developing CVD events over 
the next 10 years were taking statins to prevent stroke and myocardial infarction in 
2015 (98).  
In spite of this, the policy environment for NCD control is changing favorably as 
demonstrated by some new initiatives towards that goal. In 2013, a NCD case team 
was established under the disease prevention and control directorate of the Federal 
Ministry of Health (FMOH) with a responsibility to coordinate NCD programs (91). 
In 2014, a national strategic action plan was formulated to stimulate the 
implementation of sectoral and cross-sectoral strategies targeting the four major 
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NCDs, of which CVD is a core component (104). The first comprehensive national 
guideline for clinical and programmatic management of major NCD was launched in 
2016 (105). Moreover, Ethiopia is one of the target countries for The Lancet non-
communicable diseases and injuries (NCDI) poverty commission that aims to 
facilitate redefining the NCDI agenda nationally and at the global level 
(http://www.ncdipoverty.org/). Nevertheless, although improvements have been 
witnessed in recognizing the growing NCD problem in Ethiopia, translating this 
ultimately to ensure that the people in need of these services have actually received 
them is a question of resources availability and or the political will to commit 
resources, among other things.  
1.3.4 Health care financing 
The Ethiopian health sector remains severely under-financed with a need for 
improvement in government’s allocation for health (60, 106). According to the World 
Bank’s estimates, the health sector took 5% of Ethiopia’s GDP in 2015 (60). In 
2015/2016, the Ethiopian Ministry of Finance and Economic Development (MOFED) 
reported that 7% of the federal level budget was allocated to health sector compared 
to 25% allocation for education and road sector each and 7% allocation to agriculture 
(107).  
In terms of total government budget at regional level, about 12.5% was spent on 
health in 2015/2016 with wide variation in commitment across regions (76). In 
relative terms, Addis Ababa city administration allocated the lowest amount to health 
as share of government’s budget at 6.4% whereas, Gambella region allocated more 
than a-quarter (28.5%) of the total government budget in 2015/2016. In absolute 
terms, Somali region spent the least amount (US$ 6 per capita) compared to US$ 64 
per capita in Gambella (76). 
According to the six National Health Accounts (NHA), Ethiopia spent about US$ 29 
in 2014 in per capita terms—a significant growth from about US$ 6 in 2000 (60, 106, 
108). Still, the country’s spending falls short of the average for sub-Saharan Africa 
(US$ 98) and the recent resource requirement estimates by Stenberg et al., to meet the 
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SDG goals by 2030 —US$ 112 for low-income settings and US$ 146 for low middle-
income countries (which Ethiopia envisions to become by 2025) (109). Furthermore, 
the growth in Ethiopia’s health spending came largely at the expense of high OOP  
payments by households and support from international donors, respective 
contribution from each amounted to 34% and 50% of the total share in 2011 (Figure 
5) (106). However, government’s contribution to total health spending grew 
substantially in absolute and relative terms (from 16% of total spending in 2011 to 
30% in 2014). Nevertheless, the relative share of OOP payments by households grew 
in absolute terms and remained the same in relative terms, while development 
partner’s contribution remained the same in absolute terms and declined in relative 







Figure 5 Trend in per capita annual spending health care in Ethiopia by source of 
finance (106, 108). 
The health sector receives its financing through multiple channels (74, 110). The first 
channel draws on block grants from the treasury that are allocated to regional states 
and city administrations by the MOFED (74, 110). The finance offices at the regional 
state level in turn distribute the allocations to districts and sub-city councils within 
their catchment. The districts have the full autonomy to make allocation decisions 
based on the perceived priority needs of the population. Subsequently, district and 
sub-city authorities decide on sectoral allocations and transfer the health sector’s 
share to respective district health bureaus, which in turn make in-kind or in-cash 





















































transfers to health facilities. The second channel represents funding that flows from 
international partners to the FMOH as ear-marked funding for specific programs or in 
the form of flexible funding channeled through the pooled SDG performance fund 
which is used to cover under-funded priority programs in HSTP. The third channel 
constitutes direct transfer from development partners to implementing institutions and 
health facilities (74, 110).  
Additionally, user-fees represent another source of revenue to health facilities. The 
Ethiopian health care financing strategy allows health facilities to collect, retain, and 
use the revenues that health facilities collect—to improve the quality of services 
delivered (74, 111-113). The revenue collected at the health facility level is supposed 
to be additional to the regular budget. In 2015/2016, 225 hospitals and 3,192 health 
centers retained internally generated revenues mainly from user-fees and used them 
to purchase drugs, laboratory supplies, medical equipment, facility renovation and 
staff motivation activities among other things (17).  
The way health systems are financed has substantial impact on health service 
utilization and hence, the health of the population (1, 114-117). With this regard, 
overreliance on direct OOP payments is prohibitive to health care access and exposes 
households to financial risks (117). This is because OOP payments are often 
unpredictable and regressive in nature (1, 114-116). More explicitly, such financing 
arrangements attach payments to demand for health care instead of ability to pay. As 
a consequence, the sick with the most need for health care and the poor with lower 
ability to pay are disproportionately burdened (1, 117, 118). OOP payments could 
take the form of expenditures on consultation fees, drugs, hospital bed days, 
laboratory investigation, transportation to and from health facilities and informal 
payments to providers  (22, 119).  
In addition to their impact on health service utilization, expenditures on health care 
have long been identified among the main causes of deprivation and poverty globally, 
more so in Asia and Africa (22, 52, 120-124). Financial risk is said to occur when 
payments on health care are high relative to one’s ability to pay forcing households to 
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compromise on other essential consumptions (22, 125). In other words, it is a 
measure of the impact of health systems on non-health aspects of well-being (52). 
Therefore, progressively shifting to prepayment arrangements where the contribution 
to health system is determined based on ability to pay and not linked with health 
status or use of health services is vital to protect households from such financial risk 
and it allows risk-pooling between the poor and the rich as well as the sick and the 
healthy (1, 2, 115, 124). Measurement of financial risk and its protection are further 
discussed in the methods section.  
In Ethiopia, although households are still required to pay out of their pocket for most 
of the health services, progress has been made in shifting towards prepayment 
financing mechanisms. In 2008, the country launched a community-based health 
insurance (CBHI) scheme on a pilot basis in 12 districts in Amhara, Oromia, 
Southern Nations Nationalities and People, and Tigray regions. This voluntary 
scheme targets the informal sector and has been expanded to 191 districts in 
2015/2016 (17). Overall, only 15% of the eligible households (81% are in the 
informal sector in Ethiopia) were covered by the scheme to date. Moreover, the 
average enrolment rate stalls at 36% in 2015/2016, with the highest enrolment rate of 
50% in Tigray region and a minimum rate of 26% in Oromia region (17). In addition 
to this, preparations are under way to launch social health insurance scheme for the 
formal sector employees in the years to come (68, 113).  
Besides the challenge of low total health spending and high OOP payments I have 
discussed so far, the allocation between the different program areas seems to be 
another area for improvement in Ethiopia. In spite of the increasing burden, programs 
that target NCDs still receive very little resources (68, 74). The next five-year health 
sector strategy ,HSTP I, is estimated to cost about US$ 16 billion, with a 21% 
funding gap (68). Of this, close to 2% of total budget (US$ 300 million) is allocated 
to prevention and control NCDs (that contributes to more than one-third of the 
disease burden) compared to a ten-fold higher (21%) allocation to TB, HIV, malaria, 
maternal, new-born, child health, and nutritional conditions (68). Yet, Ethiopia is 
committed to ensure UHC that requires health system to provide health services that 
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responds to the needs of population (68). Therefore, generating relevant evidence is a 
necessary first step towards explicit priority setting for health care in Ethiopia. In the 
next section, I describe the justification for this study and the knowledge gaps that we 
intend to fill with this PhD dissertation.   
1.4 Justification of the study 
Health care resource allocation decisions have profound impact on the health status of 
the population at the aggregate level and how such benefits are distributed between 
important population subgroups. In Ethiopia, faced with an acute resource scarcity 
along with an increasing burden from NCDs, a more systematic approach to priority 
setting is needed more than ever to respond to the needs of the population in an 
efficient and fair manner. Economic evaluation is the cornerstone of priority setting 
decisions for health care resources, as misallocation of resources imply a huge 
opportunity cost in terms of healthy life year lost. However, such evidence is lacking 
in Ethiopia for most of the health conditions.    
Ethiopia spends very little on health (108). The financing is hugely dependent on 
direct OOP payments and the coverage of prepaid risk pooling mechanisms is very 
low (15, 16). The EHSP provides a basic minimum package of services free of charge 
at primary care level such as for immunization and child delivery (13). Households 
that seek care for NCDs such as CVD typically receive care upon direct payment to 
providers in public and private settings.  
Previous studies have investigated OOP spending for various health services in 
Ethiopia (126, 127). Substantial financial risks have been reported even for highly 
subsidized services and prioritized services e.g. child delivery care and treatment of 
pneumonia and diarrhea (126, 127). With the lower priority given to NCDs, it is 
expected that households with CVD could be suffering a greater financial risk for 
receiving needed health care. This is especially relevant in places like Addis Ababa 
where the burden from CVD and its risk factors is high (82, 83, 86, 87, 128). 
However, none to our knowledge have investigated financial risk related to accessing 
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CVD care in Ethiopia. Although FRP has been identified as one of the key health 
policy concerns in Ethiopia (68, 129), the recent Plos Medicine’s case study on 
Monitoring and Evaluation of progress towards UHC in Ethiopia by Alebachew et al., 
reported that none of the “direct” measures of FRP (the typically used parameters 
such as CHE) were routinely (regularly) measured and monitored in Ethiopia in 2015 
(130).  
With regards to cost-effectiveness of CVD interventions, WHO-CHOICE and the 
DCP, 2
nd
 edition (www.dcp-2.org) have evaluated cost-effectiveness of several 
population-wide and individual-based CVD interventions at regional level for East 
Africa and other regions (43, 131). However, direct transferability of such evidence  
to local decision making is limited due to differences in several parameters such as 
differences in health system organization and price of inputs (10, 42). In addition, 
several ECEA have been undertaken in Ethiopia to quantify the expected health and 
FRP gains from investing on a broad range of interventions including childhood 
immunization, caesarean section, and mental health conditions (57, 132-136). 
However, there is no systematic cost-effectiveness and extended cost-effectiveness 
analysis of a broad range of CVD interventions in Ethiopia.  
In this thesis, we intend to fill these knowledge gaps by taking Addis Ababa as an 
example due to the high burden of CVD and a greater concentration of specialized 
cardiac centers in the city. 
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2. OBJECTIVES 
This thesis aims to generate policy-relevant evidence on health outcomes, costs, and 
financial risk protection of cardiovascular disease interventions so as to inform 
priority setting decisions in Ethiopia. 
 
Secondary objectives are: 
1) to estimate the magnitude and intensity of catastrophic health expenditure and 
factors associated with catastrophic health expenditure for prevention and 
treatment of cardiovascular disease in a hospital-based cross-sectional cohort 
study in Addis Ababa.  
2) to undertake a cost-effectiveness analysis of primary prevention, acute 
treatment, and secondary prevention of ischemic heart disease and stroke in an 
Ethiopian setting. 
3) to evaluate the expected health benefits, financial risk protection, and provider 
cost of the universal public finance (UPF) of primary prevention 
(disaggregated by income quintile) among individuals at an increased risk of 




Three studies with three distinct methods were conducted to address the thesis’ 
objectives. First, a hospital-based cross-sectional cohort study was conducted to 
assess the magnitude of financial risk that households face when seeking prevention 
and treatment of CVD. Second, a CEA of a broad range of prevention and treatment 
interventions for CVD was performed to assess which services offer the best value 
for money in a potential scale-up in Ethiopia. Third, after establishing the magnitude 
of financial risk related to seeking CVD care and identifying the most cost-effective 
CVD intervention in Ethiopia, we performed an ECEA to further examine what the 
Ethiopian government could expect to gain (in terms of health and FRP) along with 
the expected cost, if decision is made to publicly finance the cost-effective 
intervention of choice. The details on the methods used in each paper have been 
published in respective papers. In the following sub-sections I give a description of 
the study setting (3.1); provide an account of the rationale behind the choice of 
analytic approaches and the outcome measures used in specific studies (3.2); and I 
end the section with a brief description of the specific methods used in study I-III 
(3.3).   
3.1 Study setting 
Study I and study III were sub-national studies, while study II was a national level 
model-based study (CEA). The Ethiopian setting has been extensively covered in the 
introduction section. Here, I shall provide a short summary about Addis Ababa and 
its population mainly focusing of data that were not covered in the introduction 
section.  
Addis Ababa is the capital city of Ethiopia. A fully urban locality, the city had an 
estimated population of 3.3 million as June 2015 with a male to female ratio of 47 to 
53 (137). In contrast with the total national population, more adults and fewer under 5 
children live in the capital—with a population dependency ratio of 38 compared to 
national average of 93 in 2015 (76). As expected, the city performs by far better than 
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the national average with respect to many of the key health and human development 
indicators as shown in Table 1. For example, in 2016, close to 90% of the pregnant 
women in Addis Ababa had four or more antenatal care visits compared to 32% at the 
national level (71). In a similar manner, close to 96% of children between the age of 
12 to 23 months have received Pentavalent-3 vaccine in Addis Ababa in contrast with 
a 53% coverage at the national level (71). The population also has a better health 
seeking behavior with an annual per capita outpatient care attendance of 1.7 
compared to a national average of 0.7 (17). 
3.2 Methodological considerations  
In this section, I give a short overview of the analytic approaches and the outcome 
measures (health and non-health outcomes) that we used together with the rationale 
behind our choice. I then provide more details on the choice of methods for each 
paper (I-III). 
3.2.1 Catastrophic health expenditures (averted) 
FRP is a way of measuring health system’s impact on individuals’ wellbeing above 
and beyond health per se (52). The root cause for incorporating FRP as one of the key 
health system objectives as well as stating it as a core element of UHC is that it is 
believed that health systems should not strive to achieve better health at the expense 
of essential consumptions that are key to the attainment of social goals other than 
health (52). Therefore, FRP is concerned with the economic impact of paying for 
health care as well as the risk protection aspect of health systems (22, 52).  
Broadly, measures of financial risk have taken four forms in the literature. 1) Using 
parameters that describe the financial burden in terms of “OOP payments as a 
function of some measure of subjects’ ability to pay”. Two of the commonly used 
threshold based metrics fall under this category—CHE and medical impoverishment. 
CHE is defined as OOP expenditure on health care exceeding a given proportion of 
resources available to households (52, 118). Resources available to households can 
be expressed in terms of total consumption expenditures or households income less of 
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expenditures on essential consumptions such as food (22). Medical impoverishment 
occurs when an individual who was originally above the poverty line drops below the 
poverty line after the OOP expenditures (52). These two measures are complemented 
by two other parameters that measure the intensity of financial risk referred to as 
mean positive overshoot (that describes the OOP payments as a share of households’ 
income or total expenditures above the chosen threshold for CHE) and poverty gap (a 
measure that intends to capture the worsening (if any) on living condition among the 
originally poor individuals due to OOP expenditures by quantifying how much 
further these households have gone below the poverty line due the payments for 
health care (22). 2) Measured as insurance value of protection against financial risk 
(money-metric value of insurance) which is quantified using risk averse individuals’ 
willingness to pay to avoid the risk of financial risk (59). 3) Expressed in relation to 
prevalence of distress financing—a parameter that intends to capture the use of 
coping mechanism to smoothen potential fluctuations in essential consumption due to 
OOP payments (122, 138). (4) Financial risk has also been expressed in terms of 
absolute $ spent on health care. For example, Waters et al., defined financial 
catastrophe as OOP spending of more than US$ 2,000 per capita per year in the US 
(119). This approach is less commonly used and it is also not preferable as it lacks 
sensitivity to individuals’ ability to pay. 
To mention some of the limitations of the commonly used financial risk measures 
(CHE and medical impoverishment): 1) these parameters do not capture the lack of 
FRP which may manifest as non-use (under-use) of health services due to financial 
barriers; 2) the “risky” nature (aspect) of direct OOP payments is not so well captured 
in these measures (52); and 3) these parameters have limitations that emanate from 
their threshold-based nature. The thresholds are meant to represent the level of OOP 
expenditure (relative to income or consumption expenditures) that is adequate to 
result in a compromise on other essential consumptions (22). However, there is no 
consensus about what might be the appropriate cut-off points for the thresholds (22). 
Typically, lower thresholds (e.g., 5%-10%) are used when income or total 
consumption is used in the denominator compared to capacity to pay measures that 
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consider expenditures net of spending on essential consumptions (e.g., 25%-40%) 
(123, 124). However, more problematic than the lack of consensus on the cut-off 
points is, by nature thresholds are not concerned about those who are just below the 
given cut-off point. For example, at 10% household income threshold level, a 
household that spent 9.9% of household income is identified as “okay”—which may 
be considered unreasonable. In the literature, some have used scenario analysis at 
different threshold levels (22), but this would not solve the problem as at any given 
threshold level the problem persists.  
In our study, we used CHE as a financial risk measure in study I and CHE cases 
averted as a measure of FRP in study III because CHE as this is a commonly used 
measure in the literature (88) and that it is advantageous because it does not 
discriminate between different population sub-groups (e.g., a single threshold can be 
applied to people with different socio-economic status—the poor and the rich) (52, 
88). We defined CHE as annual OOP expenditures on CVD care of 10% or more of 
households’ annual income. 
3.2.2 Generalized cost-effectiveness analysis (GCEA) 
CEAs are performed to inform allocation decisions about alternative courses of 
actions (21, 40). To the extent possible, all relevant alternatives should be evaluated 
with respect to their cost and consequences to avoid risk of erroneous misallocation. 
“Current practice” is a commonly used comparator. CEAs that evaluate new 
intervention(s) compared to the current practice are known as intervention mix 
constrained CEAs. (42, 139). Therefore, their application is very narrow. Besides, 
outcomes of such analysis could be misleading if the existing practice is not efficient. 
Hence, the validity of the results is highly contingent on how cost-effective the 
“current practice” is (140).  
Generalized CEA (GCEA) examines cost-effectiveness of an intervention(s) 
compared to the counterfactual of a “no intervention” scenario—that designates what 
would happen to the study population in the absence of the intervention under 
consideration (139). In so doing, GCEA expands applicability of CEA results for 
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decision making in two critical ways:1) it removes the narrow “current practice” 
constraint from the decision equation so that interventions can be assessed 
independent of the “goodness” or “badness” of the existing practice; 2) it allows 
examination of the any potential inefficiency in the “current practice”. The implicit 
assumption is that if the current practice is found less cost-effective compared to the 
newly proposed, re-allocation decisions towards a more efficient use of the resources 
(better value for money) is possible. Therefore, GCEA allows comparison of a 
broader range of  interventions so as to select the intervention mix that gives an 
optimal benefit to the society within the resource limit—a sectoral perspective (139). 
Ultimately, it helps in improving the overall allocation efficiency of the health sector 
by promoting consistent decision making across program areas. As my aim in this 
thesis is to inform macro-level priority setting decisions at the sectoral level—GCEA 
is better suited for that purpose. The GCEA approach is further discussed in the 
discussion section. 
In addition, the availability of a validated model developed by WHO-CHOICE was a 
unique opportunity to generate CEAs on a broad range on interventions e.g., 
interventions targeting maternal and child health and mental conditions. This study is 
part of a country contextualization effort with an overarching aim of informing 
sectoral level priority setting in Ethiopia.  
3.2.3 Extended cost-effectiveness analysis (ECEA)  
ECEA is one key methodological developments in health care priority setting that 
allows for evaluation of health policies with respect to multiple dimensions. 
Specifically, ECEA, is “conceived for health policy assessment to evaluate the health 
and financial consequences of health policies in four domains: (1) the health gains; 
(2) the FRP benefits; (3) the total costs of the policy to the decision makers; and (4) 
the distributional consequences” (56). As shown in the ECEA analytic framework 
presented below in Figure 6, ECEA examines health policies with respect to health 
benefits, financial risk protection gains (e.g. CHE cases averted), and the distribution 
of these benefits across sub-populations of interest (e.g., income quintiles) as well as 
 57 
the cost to the government of these gains (56). In other words, it quantifies the 
investment return from health policies in terms of health, financial risk protection, 
and equity gains (56). The unique addition of FRP in this analytic framework makes 
the tool suitable for assessing health policies’ impact in reducing financial hardship 
for households. The tool is especially suitable in low- and middle-income settings 
that lack effective health insurance mechanisms where OOP expenditures for health 
care and illness-related productivity loss expose many to catastrophic expenditure and 
medical impoverishment (56, 58). In Ethiopia, OOP payments represent a substantial 
burden to households. Therefore, FRP is one of the important dimensions for health 
policy considerations. In addition, since ECEA provides for an assessment of the 
distributional consequences of health policies, it offers a good framework to study the 
impact of conditions that disproportionately affect different sub-populations (2, 58). 
In Ethiopia, CVD risk factors and utilization of health services have gradients across 
income groups (e.g., 10% of individuals with reported angina sought care among the 
poorest quintile compared with a share of 26% among the richest quintile in 2003) 
(98, 100). These features make the ECEA a suitable analytic tool for our study. 
Therefore, ECEAs help policy makers to account for health, FRP, and equity 
considerations when allocating the limited resources in a way that meets the priority 
policy objectives. 
Policy instrument delivering a health intervention (with a 
given cost) 
 





Poorest Poorer Middle Richer Richest 
Figure 6: Conceptual framework for ECEA, reproduced from Verguet et al., (56). 
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3.2.4 Disability-adjusted life years (DALYs) 
DALY is a composite measure that quantifies the aggregate “health lost” in the form 
years of life lost due to premature death (YLL) and years of life lived with disability 
(YLD). Typically used for two main purposes: 1) to estimate the global burden of 
disease, 2) DALYs averted is used as one of the key outcome measures in CEAs—
especially in low-income settings (141). DALY is a health gap measure. It is 
something that one wants to avoid and hence, it is typically expressed as—DALYs 
averted—when used as an outcome measure in economic evaluations. Typically, 
different conditions affect distinct aspects of health: namely, length and quality of 
life. Therefore, health outcome measures using natural units such as cases of CVD 
events prevented has limited relevance for comparison across different groups. With 
this regard, DALY is advantageous in that it allows comparison between services that 
affect different aspects of health (142). For example, when we compare the health 
gains from highly fatal myocardial infraction with non-fatal depression. This makes 
the DALY powerful measure to inform resource allocation decisions across program 
areas.  
DALY is calculated as:  
                             DALY = YLL + YLD 
The YLL is straight forward, provided data on the life expectancy of a reference 
population and life expectancy of the population with the disease is available. YLL 
represents the life years lost because the person dies earlier (at age X, life expectancy 
of people with the condition at a given age) instead what could have been achieved 
without the condition (age Y, life expectancy for the reference population without the 
condition at a given age) (142). The YLL is then given by Y minus X.  
The YLD component represents the “health loss” due to the years lived with 
disability due to the condition. Each year is adjusted for quality of life measure that 
reflects the value of a year being in that state. Each health state is assigned a value 
(disability weight) on a scale of 0 (perfect health) to 1 (equivalent to death) based on 
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individuals’ preferences. Therefore, the YLD is calculated as the disability weight 
multiplied by the difference between the age of onset of the condition and age at 
death with the condition (age X). In the global burden of disease study (2013) (141), 
the health state valuation was elicited using paired comparison questions for which 
respondents were asked which of the two hypothetical individuals with different 
health states they considered worse than the comparator. The responses were modeled 
to derive the disability weights for more than 200 health states (141).  
Several criticisms have been forwarded to the DALY measure, one of them being 
health state valuation with regards to its approach to preference elicitation, choice of 
the informant, and whose preference should be used to derive the disability weights? 
Yet, the DALY measure remains an important health outcome measure in low-
income settings. We chose to use DALY as a heath outcome measure in study II and 
study III because: 1) it allows accounting for improvements in the length as well as 
quality of life which is appropriate for the interventions that we evaluated (e.g., non-
fatal stroke may result in long-term disability), and 2) it allows comparison across 
wide range of disease programs—thereby, expands the usability of the evidence we 
generated to sectoral level decision making. 
3.3 Methods used in specific papers 
3.3.1 Cross-sectional cohort study of financial risk of 
cardiovascular disease care (Paper I) 
Study population and design 
This is a hospital-based cross-sectional cohort study. Data for this study was collected 
from individuals that sought prevention and treatment services for CVD in Ethiopia’s 
capital Addis Ababa. In consultation with local experts, we selected eight hospitals in 
Addis Ababa where the study population was expected to concentrate. Overall, four 
public and four private hospitals consisting of four general and four specialized 
cardiac hospitals were selected for the study. Although primary prevention of CVD is 
provided at lower level health facilities (e.g., health centers or clinics), we focused on 
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the hospitals because chronic disease follow-up at lower level is less organized—
making the data collection process practically challenging. Therefore, we opted to 
purposively select hospitals with expected high case load and organized service 
provision for CVD prevention and treatment. 
The inclusion criteria were all adults having a diagnosis of IHD, stroke, hypertension 
or dyslipidemia, both on outpatient and inpatient basis with at least one prior 
outpatient follow up visit. We excluded those on their first outpatient visit. In each 
hospital, nurses recruited all eligible adults based on the diagnoses recorded on 
individuals’ medical charts. With the assumption that the public and private sector 
have equal role in CVD service provision in Addis Ababa, the total sample was 
distributed 50-50 between public and private hospitals. Generally, the public sector is 
the major provider of health care even in urban settings (nearly 60-40 distribution) 
(143).  
Data collection 
Data was collected through an exit interview using a structured questionnaire which 
was adapted from a tool that was used in a similar previous study in Tanzania and 
other low-income settings (94). The questionnaire was developed in English and 
subsequently translated to Amharic (the Ethiopian national language) for ease of 
administration. However, to ensure consistency, it was back-translated to English and 
pilot-tested in one public and one private hospital before the actual data collection 
began. The data collection was completed over eight weeks during February to March 
2015.  
Among other things, we collected data on participants’ socio-demographic 
characteristics, previous follow-up visits for the conditions of our interest, OOP 
expenditures on outpatient and inpatient care, source(s) of financing households used 
to cover OOP expenses, and households’ income. OOP payments constitute direct 
medical costs such as fees for consultation, hospital bed-days, drugs, and laboratory 
tests as well as direct non-medical costs such as expenses on transportation, food, and 
accommodation for patients and accompanying care-givers to and from the hospitals.  
 61 
Households’ income was defined as the average reported monthly earnings of all 
economically active members of the household net of tax through formal 
employment, self-employment, in exchange of goods or services as well as cash 
transfers from any sources including family and friends.  
Given the chronic nature of CVD, a 12-month recall period was chosen to be able to 
capture non-uniform expenditure pattern over the long term. Therefore, we gathered 
expenses on outpatient and inpatient care received at the time of data collection as 
well as for the CVD care received prior to the day of data collection at multiple data 
points.  
All monetary data were collected in Ethiopian birr (ETB) and subsequently they were 
converted to 2015 US$ using the prevailing official exchange rate that applies to the 
study period (1 US dollar = ETB 20.33) (144). An exchange rate of 4.92 ETB per unit 
$ PPP in 2011 was used for the poverty analysis.  
A total of 625 subjects were recruited for the study and 94% of them responded; five 
of them refused to participate and 31 subjects were excluded due to missing data on 
OOP payments and or households’ income. The excluded subjects were more likely 
to be from the private hospitals, otherwise they were reasonably comparable with the 
subjects included in the final analysis, e.g. with respect to residence and sex.  
Households were used as the unit of analysis. We used STATA version 14 for data 
analyses. Descriptive statistics was used to quantify the magnitude and intensity of 
CHE base on previously published methods (22). The magnitude of CHE was 
estimated as the percentage of households with annual OOP expenditure that amount 
to 10% or more of households’ annual income. Annual OOP payments on CVD care 
were estimated as the sum of estimated annual outpatient care expenditures and 
inpatient care expenditures, as appropriate.   
Whereas the intensity of financial risk among those that suffered CHE was assessed 
using a commonly cited parameter called mean positive overshoot. Mean positive 
overshoot quantifies how much more households spend (in % terms relative to 
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households’ annual income) on CVD care in a year above the 10% annual income 
thresholds that we used to define CHE. To allow subgroup analysis, households were 
divided into quintiles based on households’ income and were designated as Q1 (the 
poorest) to Q5 (the richest). T-test was used to assess the significance of the 
differences in the proportion of households that faced CHE across income groups.  
Factors associated with CHE were examined using logistic regression models. We 
selected potential covariates mainly based on the existing body of literature (94, 122, 
145). Variables were solely assessed in bivariate models for potential association, 
followed by a multivariate analysis. We examined several variables; income level (as 
categorical variable in quintiles), residence, type of hospital visited, hospitalization, 
presence of established CVD event, patient’s age, patient’s occupation, and 
household size were included in the final model. These were chosen from bivariate 
models because they were significantly associated with CHE at p-value of 0.1 (146). 
P-values of less than or equal to 0.05 and 95% confidence intervals (CIs) were used 
as cut-off points to classify respective odds ratios (ORs) as statistically significant. 
In this study, I focus on a relative measure of financial burden to take into account 
households’ ability to pay as it better informs about the economic consequences of 
OOP expenditures at the household level.  
3.3.2 Cost-effectiveness analysis of prevention and treatment of 
cardiovascular disease (Paper II) 
Cost-effectiveness analysis is a key tool that helps decision makers to select 
interventions or programs, among competing alternatives, that maximize the total 
health benefits for a given resources available (147). This is particularly relevant in 
resource constrained settings like Ethiopia, where the opportunity cost of investing in 
less-efficient alternatives could translate to huge life years lost. Here, we performed a 
GCEA of selected interventions for primary prevention, acute treatment, and 
secondary prevention of IHD and stroke in an Ethiopian setting.  
We used WHO-CHOICE’s CVD model for East Africa: a multi-stage population 
model that builds on the life-table approach to estimate health benefits in terms of 
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DALYs averted (148). The model has been validated as evidenced by the several 
regional level CEAs and country contextualization efforts in low-income settings (92, 
102, 149, 150). In this study, the regional model was populated with best available 
recent local data to the extent possible complemented by other sources when local 
evidence was lacking. A summary of the updates incorporated in the regional model 
is presented in subsequent sections.  
31 interventions (including 15 single and 16 integrated packages of interventions) 
were selected for the analysis guided by local experts’ recommendation and WHO’s 
guidelines. Detailed description of all the interventions is provided in Table 1 of 
paper II. To give a brief account here, primary prevention interventions constitute 
basic drug regimens to be delivered on an outpatient basis at primary health care 
level. This includes: (a) a beta-blocker and a thiazide diuretic at systolic blood 
pressure of > 140 mmHg or > 160 mmHg; (b) statin at serum total cholesterol level of 
> 5.7 mmol/l or > 6.2 mmol/l; (c) combination of aspirin, beta-blocker, thiazide 
diuretic, and statin at > 5%, > 15%, > 25%, and > 35% absolute risk of developing a 
CVD over the next 10-year period.  
For acute myocardial infarction, inpatient care at tertiary level with a basic 
pharmaceutical regimen consisting of aspirin, streptokinase, clopidogrel, beta-blocker 
and ACE-inhibitor and a highly skilled surgical revascularization with percutaneous 
coronary intervention (PCI) were assessed solely or in combination. Secondary 
prevention interventions constitute treatment with aspirin, beta-blocker, ACE-
inhibitor, and statin on outpatient basis at primary health care level to individuals 
with a history of established CVD events.  
Health benefits 
In order to estimate the net health gains from the interventions, subjects in the model 
were followed with and without respective interventions over a life time of 100 years. 
The model assumes that interventions are implemented only during the first 10 years 
of the follow up period. Health benefits were estimated in terms of DALYs averted. 
In the absence of local evidence, the efficacy estimates for the interventions were 
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drawn from published evidence from elsewhere. Given the current sub-optimal 
coverage of interventions (5% based on expert opinion), scaling up the proposed 
interventions to a 20% target coverage level was assessed. However, the model 
provides for eliminating the benefits from current coverage of interventions and 
adjusts the epidemiologic parameters accordingly—to create a hypothetical reference 
case of the “null scenario” which designates a simulation of what would happen to 
the study population in the absence of the interventions under consideration. Further 
details on the model design and the assumptions and inputs used are discussed at 
length in the methods section of study II.   
Costs  
As we aimed to inform health policy makers on resource allocation decisions in 
Ethiopia, we adopted a health care provider perspective to estimate the costs. 
Therefore, direct non-medical costs (such as transportation expenses) and indirect 
costs to households (such as productivity loss) were not accounted for in the analysis. 
We included program costs needed to administer the intervention as well as direct 
medical costs incurred at the point of service delivery including drug costs, hospital 
bed days and laboratory tests. An ingredient costing approach was used, where the 
quantity and respective unit prices of resources required to deliver the interventions 
were measured separately. The quantity of the resources consumed was largely 
determined based on WHO-CHOICE’s assumptions (43). Equipment and material 
prices were drawn from WHO price estimates for Ethiopia (151). The salary scale for 
the health workforce was updated based on data from the FMOH, while the price of 
relevant laboratory tests and imaging was informed by data from two public hospitals 
in Addis Ababa. The lowest ‘supplier’ price from the international drug price 
indicator guide was used to estimate unit cost of drugs (152).  
Cost-effectiveness  
Interventions were assessed in five mutually exclusive clusters within the groups 
described earlier. In each cluster, interventions were first compared with a ‘no 
intervention’ scenario. This was followed by incremental analysis within each 
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category to assess the relative cost-effectiveness of interventions starting from the 
one with the lowest effectiveness—as recommended by economic evaluation text 
books (40). Subsequently, we ranked the non-dominated interventions based on their 
cluster specific ICER—so that interventions can be prioritized for public financing in 
a step-wise manner based on their rank order until the available resources are 
exhausted—the league table approach. 
Therefore, the incremental costs for moving from an intervention to the next more 
effective intervention were divided by the incremental effects to compute respective 
incremental cost-effectiveness ratios (ICERs). Interventions that were more costly 
and less effective than their comparators or those that had higher ICER than their 
more effective comparators within mutually exclusive clusters were excluded from 
the analysis as they were dominated. The average cost-effectiveness ratios presented 
in Table 4 of study II represent the ICERs compared with a ‘no intervention’ 
scenario. And, what was reported as ICER represents results from incremental 
analysis within respective mutually exclusive categories. As recommended by WHO-
CHOICE both health benefits and costs were discounted at 3% rate annually. ICERs 
are reported as cost in 2012 US$ per DALY averted.  
In addition, we assessed the impact of uncertainties surrounding input parameter 
estimates on our final results in two ways. A probabilistic uncertainty analysis was 
undertaken using Monte Carlo simulations to assess the combined effect of 
uncertainty pertaining to the costs and effectiveness estimates. In addition, one way 
sensitivity analysis was performed to assess which one of the parameters impact the 
results the most; where we applied the lowest boundary for efficacy estimates, 50% 
of point estimates for efficacy, doubled the estimated unit price of drugs and 




3.3.3 Extended cost-effectiveness analysis of medical primary 
prevention of cardiovascular disease (Paper III) 
Study population, health policy, and estimation of the health benefits  
In this study, building on the previous two studies, we modelled UPF of a multidrug 
therapy for primary prevention of CVD with aspirin, statin, and anti-hypertensives to 
individuals with an increased absolute risk of CVD events over the next 10-years 
period according to four risk thresholds: > 5%, > 15%, > 25%, or > 35%. We 
assumed the current coverage of this multidrug therapy to be 5% and hence, we set a 
modest incremental coverage of 20% for the base-case analysis and performed 
scenario analysis for a 50% and 90% incremental coverage.  
The model was developed in two steps. In step 1, we calculated the number of people 
at each CVD risk level disaggregated by age and sex in Addis Ababa following the 
approach of study II (43, 153). To estimate the CVD risk profile of respective age–
sex groups, we updated the WHO-CHOICE CVD model for East Africa (study II) 
with the demographic data as well as the age- and sex-distribution of mean systolic 
blood pressure, mean total cholesterol level, body mass index, and prevalence of 
smoking for Addis Ababa population (85). In step 2, we estimated the number of 
CVD events prevented by the UPF policy. To do this, first, the annual number of 
CVD events without the intervention was estimated by multiplying the annual risk of 
developing acute myocardial infarction and stroke at various risk levels (154) with 
the number of individuals at each risk level calculated in step 1. This was followed by 
estimation of the expected number of CVD events averted by the intervention—
calculated by multiplying the number of CVD events without interventions by the 
intervention’s efficacy (0.54 for IHD and 0.64 for stroke) (155, 156) on annual basis 
considering the incremental coverage. All the input parameters that we used are 
presented in Tables 1 and 2 of paper III. The unit cost to the government of the 
multidrug therapy, mean OOP expenditures, and probability to CHE by income 
quintile were drawn from paper I.   
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Subsequently, the number of CVD events prevented was converted to DALYs 
averted by using the standard health economic methods: see supplementary annex of 
study III for the details. In the absence of local data on the distribution of CVD 
incidence, we disaggregated the health gains into income quintiles from Q1 (poorest 
20%) to Q5 (richest 20%) based on a study from India (157).  
Provider costs 
Under the proposed UPF policy, the government covered the direct medical costs 
related to the multidrug therapy at primary health care level. Therefore, the analysis 
did not take into account direct non-medical costs and potential income loss resulting 
from the illness. The unit cost per treated person per year was assumed to be US$ 25 
per year (153). We estimated the total costs by multiplying the number of individuals 
treated with this preventive policy by the unit cost for the respective incremental 
coverage levels. All future costs and health benefits were discounted at a rate of 3% 
per year. All monetary values were reported in US$ 2015.  
Household out-of-pocket expenditure averted 
The UPF policy is expected to protect households from incurring OOP payments in 
two ways: 1) OOP expenditures for primary prevention—estimated by multiplying 
the mean OOP payments for primary prevention in each quintile (presented in Table 
2 of paper III) by the number of individuals expected to receive the preventive 
intervention at the current coverage level (5%), 2) potential OOP payments for the 
CVD events prevented—estimated as the product of the mean OOP payments for the 
treatment and secondary prevention of CVD events in each quintile by the number of 
CVD events prevented for the incremental coverage (20%). The sum of these two 
estimates gave the total OOP expenditures averted by the UPF policy.  
Catastrophic health expenditures averted 
In a similar manner, we estimated the total number of CHE cases averted by the UPF 
policy as the sum of the CHE cases averted when seeking primary prevention before 
the policy and the CHE cases averted because of the CVD events prevented by the 
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policy. The prior was estimated as a product of the number of individuals expected to 
receive the preventive intervention at the current coverage level (5%) by the 
probability of CHE conditional on seeking care. Whereas, the latter was estimated by 
multiplying the number of CVD events prevented by the policy for the chosen 
incremental coverage (20%) by the probability of CHE for CVD treatment and 
secondary prevention based on data extracted from study I (Table 2 of study III). The 
product was subsequently multiplied by the probability of seeking health care 
conditional of having the CVD events (Table 2 of study III).  
These steps for estimation of the health benefits, OOP expenditures, CHE cases 
averted, and costs were repeated four times for all the risk thresholds to estimate the 
gains disaggregated at the four risk levels. Subsequently, these estimates were 
summed up to get the total benefits and costs of the UPF policy. Moreover, although 
a 10-year time horizon was used for the analysis; all outcomes were reported on an 
annual basis. 
3.4 Ethical approval 
The whole project has been reviewed and exempted by the Norwegian Regional 
Research Ethics Committee as it was beyond their scope. Study I was approved by 
the Scientific Ethical Review Committee of the Ethiopian Public Health Institute 
(EPHI) with a reference number: 005-02-2015/EPHI 6.13/65. We also obtained 
informed consent from study participants before commencing the interviews for the 
data collection. In addition, data was stored and used in de-identifiable form to ensure 
confidentiality. Study III is the extension of study I and benefited from the same 
primary data used in study I. Study II is a modelling exercise that fully used publicly 




In this section I present the results from the three studies that this thesis was founded 
on. In study I, we estimated the financial risk households faced related to seeking 
prevention and treatment of CVD in Addis Ababa. Study II explored cost-
effectiveness of a broad range of CVD interventions that the Ethiopian government 
could consider for a potential scale-up to successfully control the growing CVD 
burden. In study III, we estimated the expected investment return that the government 
can anticipate to gain from scaling-up the most cost-effective strategy that we 
identified in Study II with respect to health and FRP gains and assessed the 
distribution of these benefits across income quintiles of the at-risk population. The 
results are presented below under each sub-section. 
4.1 Synopsis of paper I: 
Financial risk of cardiovascular disease care.  
A total of 589 subjects were included in the final analysis. Of them, close to 85% 
were 45 years old or above and about half of them were engaged in an economically 
productive job during the survey (see Table 2). The majority of the participants (80%) 
were residents of Addis Ababa, while the remaining travelled from outside the city to 
seek CVD care. About 54% had established CVD events, including the 6% that were 
hospitalized for it during the survey period; the rest were on primary prevention 
regimen. Further details on the socio-economic characteristics of the study population 






Table 2 Socio-demographic characteristics of study 
participants. 
 
  N=589 (%) 
Age( in years) 
25-44 88 (15) 
45-64 281 (48) 
65-79 192 (32) 
> = 80 28 (5) 
Gender 
Female 298 (51) 
Male 291 (49) 
Marital status 
Single 51 (9) 
Married 428 (73) 
Divorced 26 (4) 
Widowed 84 (14) 
Residence 
Addis Ababa 470 (80) 
Outside Addis 119 (20) 
Education 
No formal education 115 (20) 
Grade 8 or less 163 (28) 
Grade 9-12 146 (25) 
Diploma 85 (14) 
Bachelor degree+ 80 (13) 
Occupation 
Government employee 119 (20) 
Private employee 38 (6) 
Private business 109 (19) 
Stay home mum 162 (28) 
Retired  135 (23) 
Other  26 (4) 
Diagnosis 
Ischemic heart disease 233 (40) 
Stroke 83 (14) 
Hypertension 235 (40) 
Dyslipidemia 38 (6) 
Number of hospital 
admission(s) over the 
last 12 months  
0 489 (83) 
1 90 (15) 
2 10 (2) 
Type of hospital visited 
Public 306 (52) 
Private 283 (48) 
 
In total, about 27% (CI [21.1, 30.6]) of the study subjects faced financial 
catastrophe—having an annual spending on CVD care that exceeds 10% of 
household annual income. The financial risk was unevenly distributed across income 
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quintiles, although it seems to be non-monotonic. Notably, 28% (CI [20.0, 37.3]) of 
the poorest quintile had CHE compared to 14% (CI [7.9, 23.1]) among the richest—
which was statistically significant (p-value comparing the two proportion was 0.02) 
(see Table 3 below). 
Table 3 Proportion of households that faced catastrophic out-of-pocket 
payments for prevention and treatment of cardiovascular disease in 





[95% CI] † 
Total 26.7 1.9 23.1 30.6 
Q1 27.9 4.4 20.0 37.3 
Q2 28.5 3.8 21.7 36.6 
Q3 32.2 5.0 23.3 42.6 
Q4 28.3 4.1 21.0 37.0 
Q5 13.9 3.8 7.9 23.1 
*standard error of the mean, †95% confidence interval, p-value 
comparing Q1 and Q5 = 0.015. 
 
The results from the logistic regression analysis are presented in Table 4 below. 
Several factors were found to be significantly associated with CHE. To give 
examples, hospitalization for CVD events increased the odds of CHE by about eight-
fold (OR = 8.4 [4.2, 16.6])—stroke being the strongest predictor (OR = 4.1 [1.8, 
9.2]). Likewise, households that travelled to Addis Ababa to seek CVD care faced a 
greater financial risk compared to Addis Ababa residents (OR = 3.3 [1.8, 5.9]), as 
was the case for those that sought CVD care in private hospitals (OR = 20.7 [20.2, 
42.1]). More importantly, CHE was found to have a strong negative association with 
income group. The odds of CHE among the poorest quintile was significantly higher 
than that of the richest quintile (OR = 58.6 [16.5, 208.0]). The ORs decline steadily as 
the income group increases, although the CIs were wide (Table 4).    
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Table 4 Multiple logistic regression analysis of factors associated with catastrophic 
out-of-pocket payments for prevention and treatment of cardiovascular diseases in 






Q1 58.6 [16.52, 208.0] 0.00 
Q2 39.0 [11.87, 128.24] 0.00 
Q3 20.9 [6.97, 62.92] 0.00 





Addis Ababa 1 
 
  
Outside Addis 3.25 [1.79, 5.90] 0.00 
Type of hospital visited 
Public  1 
 
  
Private 20.71 [10.21, 42.05] 0.00 
Received in-patient care for 





Yes 8.39 [4.24, 16.59] 0.00 
Diagnosis* 
IHD 1.15 [0.65, 2.06] 0.63 






Household size Household size 1.20 [1.06, 1.36] 0.04 
Age of participants Patient’s age 1.00 [0.98, 1.02] 0.02 
Duration since diagnosed Duration since diagnosed 0.99 [0.98, 0.99] 0.05 
Occupation of participants 
Employed† 1.07 [0.44, 2.58] 0.88 
Private business 0.91 [0.38, 2.17] 0.84 
Housewife/househusband 1.34 [0.67, 2.65] 0.41 
Retired  1   
Others 1.23 [0.36, 4.14] 0.73 
 * IHD stands for ischemic heart disease, Q1 stands for poorest quintile and Q5 stands for 
richest quintile. †includes government and private employees 
 
In addition, we found that the bottom two quintiles spent about 24% more of 
households’ annual income on CVD care, while the richest quintile had only 5% extra 
spending (Table 4 of paper I). This indicates a more severe financial risk among the 
poorest.  
As expected, households used various coping mechanisms to cover OOP 
expenditures—more so for inpatient care than for outpatient care. As shown in Table 
5 of study I, family support was the predominant means. About 40% of households 
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fully covered inpatient care expenditures through family support, while another 30% 
tapped into this source to cover outpatient expenditures. A smaller proportion of 
households (5% for outpatient and 15% for inpatient care) used their savings (see 
Table 5 of study I). Dependence on family support tends to be common among the 
poorer households compared to the better-off (result not shown). 
We now know that households in Addis Ababa faced a sizeable financial risk when 
seeking prevention and treatment services for CVD and that this financial risk 
unevenly affected the poor and those with established CVD events among others.     
4.2 Synopsis of paper II: 
Cost-effectiveness of prevention and treatment of cardiovascular disease.  
Of the 31 interventions we assessed, combination drug treatment with anti-
hypertensives, aspirin, and statin based on individuals’ absolute risk was found to be 
the most cost-effective (see Table 5 below). The ICER for this package was US$ 67 
per DALY averted, if initiated at the highest risk threshold level (> 35%). The 
incremental cost per an additional DALY averted increased moderately at lower risk 
levels— and reached US$ 340 at the lowest risk (> 5%) (Table 5). The absolute risk 
based approach dominated the alternatives that targeted high blood pressure and high 








Table 5 Annual cost, annual health benefits and cost-effectiveness ratio and ICER ranking 








Combination drug treatment for 
absolute risk of CVD > 35% 
7.18 107,687 67 67 
Combination drug treatment for 
absolute risk of CVD > 25% 
9.83 127,712 77 131 
Combination drug treatment for 
absolute risk of CVD > 15% 
14.41 153,877 94 177 
Combination drug treatment for 
absolute risk of CVD > 5% 
26.85 190,391 141 341 
Acute IHD: ASA+streptokinase 
+ACE-inhibitor+beta-blocker 
2.92 2919 999 999 
Sec. prev. stroke: ASA+ statin 
+ ACE-inhibitor 
3.48 3,284 1,061 1,061 
Sec.prev IHD: 
ASA + beta-blocker + statin + 
ACE-inhibitor 
2.88 1,557 1,849 1,849 
Acute IHD: ASA+ clopidogrel 
+ PCI 
8.50 4,015 2,115 5,087 
ACER stands for ICER compared to null scenario, ICER stands for cluster specific ICER, 
IHD stands for ischemic heart disease, PCI stands for percutaneous coronary intervention 
 
Generally, treatment and secondary prevention of CVD was relatively less cost-
effective than primary prevention. Among the alternatives for treatment of acute 
myocardial infarction, an integrated package of aspirin, ACE-inhibitor, beta-blocker, 
and streptokinase generated the most value for money within its cluster (ICER = US$ 
1,000 per DALY averted). Notably, the incremental cost for an additional DALY 
averted escalated by a factor of five when moving from this basic integrated package 
to a package that consisted of PCI, aspirin, and clopidogrel (ICER = US$ 5,100 per 
DALY averted) (Table 5).  
Provision of interventions in packages improved interventions’ cost-effectiveness. 
Accordingly, for secondary prevention of IHD, a package of aspirin, beta-blocker, 
ACE-inhibitor, and statin (costing US$ 1,850 per DALY averted) was relatively more 
cost-effective than its comparators, as was a package of aspirin, ACE-inhibitor and 
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statin (for costing US$ 1,060 per DALY averted) for secondary prevention of stroke 
within its respective cluster (Table 5).  
However, the results from the probabilistic sensitivity analysis presented in Figure 1 
of paper II revealed substantial uncertainty surrounding the costs and effectiveness 
estimates of the interventions. The level of willingness to pay was shown to have a 
meaningful impact on the probability of a given interventions being cost-effective. 
On the other hand, the results from the one-way sensitivity analysis demonstrated that 
halving the effectiveness assumption had modest effect on the ICER estimates, while 
other changes (e.g., unit costs) had little or no effect (Table 5 of paper II). However, 
the outcomes from these scenarios did not change the conclusions about the results of 
the paper. 
4.3 Synopsis of paper III 
Health benefits and financial risk protection from cardiovascular disease 
prevention.  
This study estimated the costs and the expected health and FRP gains from UPF of 
multidrug therapy for primary prevention of CVD in Addis Ababa—the most cost-
effective intervention among those assessed in study II. Overall, the UPF policy 
afforded significant health and FRP gains that preferentially benefited the poorer 
households.  
For a 20% incremental coverage, the UPF policy would avert about 5,800 DALYs 
per year in total. The largest health gain—2,240 DALYs averted per year—would be 
attained at > 15% risk level, while 1,240 (at > 35%), 1,180 (at > 25%), and 1,200 (at 
> 5%) DALYs would be averted (at respective risk levels). The DALYs averted were 
distributed across income as: 22% (Q1), 18% (Q2), 24% (Q3), 26% (Q4), and 10% 
(Q5)—a pattern consistent regardless of risk level chosen (Table 6).  
 
Table 6 Annual health benefits, financial risk protection and costs of 20% increased coverage of 
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universal public finance of primary cardiovascular disease prevention in Addis Ababa, Ethiopia, 
2015. 
 Income quintile 
1 2 3 4 5 Total 
Total DALYs averted (discounted) 
Absolute risk>35% 270 230 290 320 130 1 240 
Absolute risk>25% 260 220 270 310 120 1 180 
Absolute risk>15% 490 410 530 580 230 2 240 
Absolute risk>5% 260 220 290 310 120 1 200 
Total 1,280 1,080 1,380 1,520 600 5,860 
Number of catastrophic health expenditure cases averted  
Absolute risk>35% 22 18 21 23 12  96  
Absolute risk>25% 28 23 26 23 16  116  
Absolute risk>15% 55 47 51 58 31  242  
Absolute risk>5% 91 78 79 93 52  394 
Total 196 166 177 197 111 848 
Total household out-of-pocket expenditures averted (in 2015 US$, discounted) 
Absolute risk>35% 18,600 24,900 22,500 31,500 31,200 128,700  
Absolute risk>25% 24,000 31,700 28,700 38,700 37,600 160,700  
Absolute risk>15% 48,100 63,800 55,900 75,000 74,200 317,000 
Absolute risk>5% 80,100 106,400 88,200 115,400 116,800 506,900 
Total 170,800 226,000 195,300 260,000 259,800 1,113,300 
Total cost of UPF of primary prevention to government (in 2015 US$, discounted)
b
 
Absolute risk>35% 39,300 39,300 39,300 39,300 39,300  196,500 
Absolute risk>25% 50,800 50,800 50,800 50,800 50,800 254,000 
Absolute risk>15% 104,000 104,000 104,000 104,000 104,000 520,000 
Absolute risk>5% 192,000 192,000 192,000 192,000 192,000 960,000 
Total 386,100 386,100 386,100 386,100    386,100 1,930,500 
 
In addition, the policy would avert about 850 cases of CHE at the aggregate level. 
The FRP gain was progressive across risk levels, where 96 cases of CHE would be 
averted at > 35% risk level: while respective figures were estimated to be 116 (at > 
25%), 242 (at > 15%), and 394 (at > 5%) risk levels. About 87% of the cases of CHE 
averted would benefit the four bottom quintiles: 23% (Q1), 20% (Q2), 21% (Q3), 
23% (Q4), and 13% (Q5) (Table 6). There was no remarkable difference in the 
distributional pattern across risk levels.   
We estimated that the policy would avert more than US$ 1.1 million per year overall 
(Table 6). The OOP expenditures averted increased steadily across risk levels: in 
US$, 129,000 (at > 35%); 160,000 (at > 25%); 317,000 (at > 15%); and 507,000 (at > 
5%) would be averted annually at each risk level (Table 6). About 85% of the OOP 
expenditures averted would benefit the upper four quintiles: 15% (Q1), 20% (Q2), 
18% (Q3), 23% (Q4), and 23% (Q5) (Table 6). This holds true regardless of the risk 
level chosen.  
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The UPF policy procured these benefits with a total annual cost of US$ 1.9 million 
per year. When disaggregated by risk level, the costs translated to US$190,000 at > 
35% risk level and increased steadily at lower risk levels to reach 960,000 at > 5% 
risk level (Table 6).  
The results from the scenario analysis with a 50% and 90% incremental coverage 
predicted a substantial growth in the expected health and FRP gains in absolute terms 
(Tables A.3 and A.4 in supplementary annex of paper III). At 50% incremental 
coverage: 14,500 DALYs; 2,050 cases of CHE; and US$ 2,800,000 on private OOP 
expenditure would be averted per year with a total annual cost of US$ 4,800,000. 
Whereas, for 90% incremental coverage: 25,700 DALYs; 3,640 cases of CHE; and 
US$ 4,900,000 on private OOP expenditure would be averted per year with a total 
annual cost of US$ 9,200,000. However, in relative terms, the returns per US$ 
invested were marginally lower at higher coverage level compared to the base-case 
scenario (20% incremental coverage) (Tables A.5 and Tables A.6 in supplementary 
annex of paper III). The distribution of the benefits across income quintiles at 50% 




This thesis was set out to generate policy-relevant evidence on health outcomes, 
costs, and FRP of CVD interventions in Ethiopia. In the subsequent section, I discuss 
the main findings in view of the secondary objectives and provide interpretations of 
the results followed by a brief discussion of the key strengths and limitations of the 
methodological approaches that we used in the three papers.  
5.1 Main findings 
In study I, we found that more than a quarter (27%) of the households that sought 
prevention and treatment of CVD in hospitals in Addis Ababa faced CHE. Low 
income was a strong predictor of a higher magnitude and severe intensity of financial 
catastrophe. The households that faced CHE among the bottom quintile spent about 
24% of households’ annual income over the CHE threshold compared to a 5% excess 
among the top quintile. Hospitalization, established history of CVD events especially 
stroke, seeking CVD care in private hospitals, larger family size, and residence 
outside Addis Ababa were among the key determinants of higher likelihood of CHE.  
Study II revealed that primary prevention of CVD with a multidrug regimen 
composed of aspirin, antihypertensives, and statins to individuals at increased CVD 
risk generated the most value for money of all the interventions that we assessed. 
This preventive package was estimated to cost about US$ 67 per DALY averted at > 
35% absolute risk level with a modest increase in the ICER at lower risk levels. 
Within the acute myocardial infarction category, a package of aspirin, streptokinase, 
ACE-inhibitor, and beta-blocker dominated its comparators and costed about US$ 
1,000 per DALY. However, when one moves from this basic pharmaceutical package 
to package that contained aspirin, clopidogrel, and PCI—the ICER escalated to US$ 
5,100 per an extra DALY averted. The secondary prevention packages consisting of 
aspirin, ACE-inhibitor, beta-blocker, and statins for IHD (ICER = US$ 1,850 per 
DALY averted) and stroke (ICER = US$ 1,060 per DALY averted) were found to be 
less cost-effective than medical primary prevention.  
 79 
Study III estimated that, in total, the UPF of medical prevention of CVD would avert 
5,860 DALYs, 850 cases of CHE, and US$ 1.1 million on private OOP expenditure 
per year at an annual cost of US$ 1.9 million for a 20% incremental coverage. When 
disaggregated by risk level, the DALYs averted ranged from 1,180 (at > 25%) to 
2,200 (at > 15%); the number of CHE averted ranged from 96 (at > 35%) to 394 (at > 
5%); OOP payments averted ranged from US$ 129,000 (at > 35%) to US$ 510,000 
(at > 5%); the costs to the government ranged from US$ 196,000 (at > 35%) to 
960,000 (at > 5%). Both health and FRP gains would disproportionately benefit the 
poorer households. 
5.2 Interpretation and comparison of results  
5.2.1 Financial risk of cardiovascular disease care (Paper I) 
This study is the first to examine financial risk related to seeking CVD care in 
Ethiopia. Consistent with the existing body of literature from several low- and 
middle-income countries (94, 125, 158-160), our findings uncovered the existence of 
sizeable financial risk that households faced when seeking prevention and treatment 
of CVD in hospitals in Addis Ababa (161).  
Generally speaking, the magnitude of CHE that we found (27%) was relatively lower 
in contrast with a range of 55%-85% reported by others from Tanzania, India, and 
China (94, 125). We have given a detailed account the possible explanations for this 
seemingly low magnitude of CHE in the discussion section of study I. Of the possible 
explanations provided, under-utilization of CVD services is among the most relevant. 
According to the recent STEPS survey, only about 12% of the individuals aged 40-69 
years with established CVD events or having 30% or more risk of developing CVD in 
the next 10-years were taking statins and counseling for prevention of heart attack or 
stroke, while 97% of the hypertensive individuals reported not taking any medication 
for it (98). Financial reasons are among the major barriers to access health services in 
Ethiopia, especially among the poor (15, 16). In 2015/16, 48% among the poorest 
quintile reported lack of money or high cost of health care as the main reasons for not 
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seeking health care for reported illnesses compared to a rate of 12% among the 
richest quintile (16).   
As discussed in the methods section, parameters such as CHE do not capture the 
prohibitive impact of OOP expenditures on health service utilization that often 
manifest as non-use or under-utilization of services due to financial reasons (22, 52). 
As a consequence, such parameters could seem low (erroneously indicating a good 
FRP) when service utilization is far from optimal (52). In response to this 
methodological deficit, the WHO and World Bank group suggested these parameters 
should be evaluated together with service coverage indicators so as to get a fuller 
picture of the FRP situation (53).  
Moreover, we found that the poorest quintile faced a greater magnitude and intensity 
of financial risk compared to the richest quintile. These findings are in line with 
several previous studies (93, 94, 125, 158-160). For example, in a recent assessment 
of progress towards UHC in Bangladesh, Islam et al., reported higher financial risk 
among the poor, those that received inpatient care, and households with a member 
affected by chronic diseases (162). The higher magnitude of CHE among the poor in 
the Ethiopian setting is further compounded by higher prevalence of CVD risk factors 
and poorer access to health care among this sub-group compared with the richer sub-
populations (100). 
Health financing systems that overly rely on OOP payments expose households to 
substantial financial risk (1, 117). The principle of fairness in contribution —one of 
the key considerations for a fair progress towards UHC—requires dissociating use of 
and payment for health services and that it dictates contribution to health financing 
systems be determined based on individuals’ ability to pay regardless of their health 
status or demand for care (2, 12). OOP payments violate this principle in two ways. 
Typically, individuals pay a flat rate when receiving services regardless of their 
ability to pay (1). As a consequence, the poor and the sick are taxed more with such 
payment arrangements—which is considered unfair (1). The resultant effect of this 
could be far reaching—to the extent of denying access to needed health care, cause 
 81 
financial hardship, and related medical impoverishment (117). Therefore, reducing 
OOP payments especially for high priority services and progressively shifting to 
prepayment mechanisms is key to protect households from such unwanted 
consequences (1, 2). Well-regulated prepayment and risk pooling arrangements have 
been shown to be effective in reducing financial risk and in promoting equitable 
access to health care (1, 2, 163).  
The challenge now is how to progressively shift to prepayment arrangements and 
how to prioritize services for coverage. The Making fair choices on the path to UHC 
report stressed the need to begin with the high priority services and reduce or 
eliminate OOP payments for such services first (2). In addition, Gwatkin and Ergo—
in what they termed progressive universalism—argued that unless countries put an 
intentional effort not to leave the poor behind (20), the movement towards UHC 
might have an unprecedented negative effect on the poor. Three pathways have been 
proposed to ensure inclusion of the poor in this endeavor: 1) to provide a package for 
all that consists mainly of services addressing the needs of the poor, 2) to have a 
broader package of services for all and exempt the poor from the required financial 
contributions (5), and 3) start with high priority services and exempt either selectively 
the poorer households or all depending on the feasibility of employing effective 
mechanisms to mobilize the “lost” revenue for the health system in question (2, 164).   
So far, Ethiopia has offered a very basic list of services to all citizens based on an 
essential package defined more than a decade ago (13). Furthermore, the fee-waiver 
scheme—targeted at the poorest of the poor individuals—extended access to health 
care to about 1.5 million people in 2015 (17) (which is less than 2% of the total 
population in a country where more than 30% of the population lives under the 
poverty line). In addition to its sub-optimal coverage, the effectiveness of the fee-
waiver scheme was compromised by its less-effective targeting, where the 
beneficiaries were nearly evenly distributed across the bottom four quintiles (15).   
In addition, under the CBHI scheme that reached out to the informal sector in over 
190 districts, the federal government pays 25% of the premium for all beneficiaries 
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while, the local governments subsidize the poorest households within their catchment. 
However, although the CBHI scheme showed a positive trend in improving health 
service utilization and protecting beneficiaries from financial risk associated with 
health service utilization (111, 165), the scheme enrolled only 15% of “the potential 
beneficiaries” in 2015 (17). 
When such formal mechanisms fail to provide the much needed protection against 
financial risk, households are forced to resort to several coping mechanisms (e.g., 
borrowing, asset sale, and support from family and friends) (117)—as was the case in 
our study. Several studies have also showed high prevalence of such coping 
mechanisms in many low-income settings (122, 138). We found a huge reliance 
particularly on support from family in our study—more so for inpatient care and 
among the poorest households. It is generally believed that these coping mechanisms 
would help households to smoothen the potential fluctuations in essential 
consumptions due to the “unexpected” OOP expenditures (22, 122, 166). However, I 
argue that the naïve assumption that such mechanisms have only positive impact 
could be misleading. In our study, it was the poorest households who were more 
dependent on such mechanism—support was mainly sought from their adult off-
springs who are more likely to be poor as well, while the richest households were 
tapped more into their income and savings—indicating a potential trans-generational 
effect of lack of FRP. 
Finally, due to the emerging changes in epidemiologic and demographic patterns (see 
Figure 2) and a positive economic prospect, there is a need for the revision of the 
EHSP to accommodate the evolving health needs of the Ethiopian population. As it is 
now, the EHSP to a large extent excludes even the “best-buy” NCD services (103)—
CVD included (13). Given the resource scarcity, the revision requires due attention to 
relevant evidence and transparent processes to ensure efficiency in the use and 
fairness in the allocation of the limited available resources—to which we hope to 
contribute through this thesis.   
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As expected, having established CVD events, especially stroke was associated with 
higher financial risk. This can confirm the expectation of the potential of scaling-up 
primary prevention of CVD in conferring FRP to households through averting 
possible future expenditures by reducing incidence of CVD events. Therefore, 
evidence on the relative cost-effectiveness of alternative strategies is crucial to 
identify the CVD interventions that deserve high priority in a potential scale-up. This 
is what we did in study II and the results are discussed in the next section.  
5.2.2 Cost-effectiveness of prevention and treatment of 
cardiovascular disease (Paper II) 
In study II, we performed a GCEA where we evaluated five sets of mutually 
exclusive intervention clusters for prevention and treatment of IHD and stroke, 
followed by ICER ranking across clusters. Accordingly, primary prevention with 
combination of aspirin, antihypertensive, and statin to individuals with an increased 
absolute CVD risk was more cost-effective than the single risk factor based 
approaches for primary prevention as well as the treatment and secondary prevention 
measures that we assessed. These findings are in harmony with others’ findings in 
sub-Saharan Africa and other low-income settings (92, 131, 167). The ICERs we 
estimated for specific interventions were also within a close margin with the results 
of previous studies from sub-Saharan Africa by Ortegon et al., and the DCP, 2
nd
 
edition (92, 131).  For example, at > 35% risk threshold, we estimated the ICER for 
medical primary prevention to be US$ 67 per DALY averted compared to $ 104 per 
DALY averted estimated by Ortegon et al., in sub-Saharan Africa (92). In a similar 
manner, the ICER estimates for acute myocardial infarction and secondary prevention 
packages were within a close range with the DCP, 2
nd
 edition estimates for the same 
region (131). For example, the DCP, 2
nd
 edition estimated an ICER of $ 1,955 per 
DALY averted for a secondary prevention package of IHD consisting aspirin, statin 
and beta-blocker compared to our estimate of $ 1,850 per DALY averted for the same 
package.  
Although the aim of study II was to explore cost-effective CVD strategies that 
Ethiopia could consider for a potential scale-up to halt the growing CVD burden in its 
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narrower version; this aim is embedded in an overarching goal of informing macro 
level priority setting decisions for health care in Ethiopia—for which GCEA is better 
suited especially when evidence is available on cost-effectiveness of a broad range of 
services from the same setting (30, 139). With this broader aim in mind, when we 
compare our results with results of Strand et al., (149), the CEA of mental health 
services in Ethiopia, except for the acute myocardial infarction package that 
contained aspirin, clopideogrel, and PCI (with an ICER of 5,200 per DALY), most of 
the CVD interventions that we assessed fared either favorably (e.g., primary 
prevention with a multidrug therapy) or fairly equivalently (e.g., secondary 
prevention packages for IHD and stroke (ICER = US$ 1,000 to US$ 1,850 per DALY 
averted) compared with new anti-depressants with psychotherapy (ICER = 1,026 per 
DALY averted, lithium combined with psychosocial treatment for bipolar disorder 
(ICER = 1,807 per DALY averted).  
In contrast with the maternal and neonatal health services that were evaluated by 
Memirie et al., (168), the multidrug therapy based on the absolute CVD risk still 
compared well with most interventions except for a few interventions with very low 
ICER such as the Kangaroo mother care (ICER = US$ 9 per DALY averted). 
Therefore, we can conclude that medical primary prevention is as cost-effective as 
well recognized high priority services with respect to cost-effectiveness e.g., safe 
abortion care (ICER = US$ 198 per DALY averted) or tetanus toxoid for pregnant 
women (ICER = US$ 59 per DALY averted). Our findings come against the general 
expectation that NCD interventions are too costly to be considered for scale-up in 
low-income settings such as Ethiopia.  
An advantage of the GCEA is that it obviates the very context-specific “current 
practice” constraint from the ICER calculations of particular interventions, as 
comparison is made between the intervention of interest and the “null scenario” 
within the GCEA framework (139). Hence, our ICER estimates were not affected by 
the “cost-ineffective comparator” or “incomparable comparator” problem that league 
table approaches are criticized for (140). Furthermore, the comparison of these three 
GCEAs from Ethiopia was deemed reasonable. This is because the commonly cited 
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differences between CEAs—with respect of certain methodological considerations—
were fairly similar across these three studies (149, 153, 168). Some of these 
methodological considerations include the year of origin, choice of comparator, the 
health system context, choice of the perspective for the analysis, costing assumptions, 
discount rate, source of disability weight (169). Hence, the comparisons could be 
considered reasonable. 
In CEAs, when the intervention under consideration generates additional health 
benefits with an extra cost requirement, one needs to examine the value of what is 
likely to be given up by not investing these same resources (required for the  
intervention under consideration) in the next best alternative use—to be able to judge 
whether the additional costs required is justifiable (40). This is what economists 
call—the opportunity cost. With a fixed health budget assumption, choosing to 
finance an intervention automatically translate to less resources available for the next 
best alternative within the health sector. The opportunity cost, then, represents what is 
likely to be given up, in terms of health foregone, as a result of the allocation decision 
(40). This benchmark is typically expressed as a cost-effectiveness threshold in the 
economic evaluation literature and is defined by Woods et al., as “the amount of 
money that, if removed from the health care system, would result in one less unit of 
health being generated, or equivalently, the cost of generating an extra unit of health 
in the present health system” (170). In other words, the threshold is the marginal cost 
of producing an incremental unit of health within the existing health care system. 
Therefore, interventions that consume less than this cost-effectiveness threshold to 
produce an additional unit of health benefit are considered cost-effective, while those 
that require more than this amount are deem cost-ineffective because the resources 
they consume would generate greater health benefits if used to fund other high 
priority services within the existing system.   
The long standing threshold recommended by WHO as a multiple of national GDP 
per capita (one to three times) was in use widely to guide resource allocation 
decisions since its introduction in 2001 (43). Recently, however, Revill et al., 
criticized this threshold for its lack of empirical foundation and warned that the 
 86 
continued naïve use of the threshold might result in unprecedented loss of lives and 
worsen health inequality (171). For example, some services might have a favorable 
ICER based on the three times GDP threshold, but it might be that the resources 
required to fund the newly accepted service might displace more cost-effective 
options or crowd-out resources that could have been made available for services that 
are relatively more cost-effective (172). In addition, by simply accepting services for 
financing on the grounds of such thresholds, one might overlook the notion of 
affordability, feasibility, and the required implementation costs—resulting in an 
unprecedented escalation of health care expenditures (30, 140, 172-174).  
Based on an empirical assessment of the opportunity cost, Revill et al., recommended 
a range of 1-51% of national GDP per capita as a reasonable cost-effectiveness 
threshold for low-income settings such as Ethiopia (171). Informed by their 
recommendation, I used a 51% GDP per capita threshold to represent a reasonable 
(efficient) use of health care resources in Ethiopia: which translates to US$ 315 per 
DALY averted in 2015 US$. This is not, however, to suggest that we should use the 
proposed threshold in isolation; even if it was informed by some empirical analysis, 
other  relevant considerations remain crucial to priority setting decisions e.g., the 
feasibility of implementation and implementation costs of the services under 
consideration (172).  
According to the proposed cost-effectiveness threshold (US$ 315 per DALY 
averted), we can conclude that except the multidrug regimen for primary prevention 
of CVD, the packages for treatment and secondary prevention of CVD are not cost-
effective in the current Ethiopian setting. Given this background, if for example, the 
Ethiopian government choses to invest in the acute myocardial infarction package 
that contain PCI, aspirin, and clopideogrel (ICER = US$ 5,100 per DALY). This 
means that the Ethiopian population would have gotten about 17 times (ICER of the 
package / cost-effectiveness threshold) more health if these same resources were used 
for other higher priority interventions. Alternatively, if the same resources were used 
to scale up medical prevention at > 35% risk level—about 77 times more DALYs 
would have been averted. Therefore, choosing cost-ineffective services could be very 
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unfortunate and has a magnificent negative impact on the total health of Ethiopian 
population. This is what WHO’s consultative group on equity and UHC refer to as 
“unacceptable trade-off # I”—expanding coverage of medium low priority services 
before a near-universal coverage is achieved for high priority services (2, 175).  
On a related note, Birch and colleagues challenged the theoretical assumptions 
underlying the application of the league table approach in informing priority setting 
decisions with a limited budget context in real world case (140, 174). The league 
table approach has two fundamental assumptions—a perfect divisibility of services 
and constant rate of return for a proportional investment (21, 176). However, these 
two assumptions may not always hold true in reality (140, 174) e.g., these principles 
may be violated for practical (when it is not possible to implement a “portion” of the 
next eligible service on the list with the budget left) or ethical reasons (for mutually 
exclusive interventions, one can be ethically challenged for giving a “better” 
alternative for those that receive services later than earlier). In such situations, the 
suggested  alternatives include the use of computer programs to arrive at alternative 
combinations of services that maximize total benefit within the budget limits (176).  
When planning for expanding the coverage of services in the absence of adequate 
additional resources that match the extra resource requirements—an inevitable 
consequence is disinvestment. According to Williams et al., disinvestments can take 
the form of retraction (“investing in less of an intervention’), restriction (‘withdraw 
an intervention from certain groups’), or substitution (‘replacing an intervention with 
one deemed more efficient’) (30). In Ethiopia, displacement is an inevitable 
consequence of any decision to expand the publicly financed basket of health services 
as evidenced by the trend in health care financing in Ethiopia (discussed in the 
introduction section) (106, 108). Particularly, given the lower attention paid to NCDs 
so far, decisions to cover cost-effective services targeting common NCDs in the 
essential health services package (e.g., multidrug therapy for primary prevention of 
CVD) may entail hard investment choices and trade-offs to be made. However, I do 
not anticipate this to be realized in the form of substituting other basic high priority 
cost-effective services (e.g., treatment of childhood diarrhea) if there is openness to 
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carefully appraise current investment choices in Ethiopia’s health sector beyond the 
essential package.  
In recent years, it is not uncommon to see public funds being allocated for expansion 
of costly services such as dialysis for end-stage renal disease and high tech 
radiotherapy machines in public tertiary hospitals, while the country still lags behind 
in full coverage of high priority basic services. The net effect of public finance of 
such costly services on the health of the Ethiopian population, although could be 
beneficial to the families affected by these conditions, would be negative. Therefore, 
in the face of extreme resource scarcity, investment choices should be subject to open 
scrutiny against an agreed set of criteria or guiding principles when selecting 
interventions for prioritized public financing so as to avoid the potential huge 
opportunity costs. I will illustrate this point using the following example.  
Studies in Malaysia and Thailand estimated that haemodialysis for end-stage renal 
failure costs roughly about US$ 10,000–US$ 15,000 per healthy life year saved  (177, 
178). Let us simplify this and assume that haemodialysis costs US$ 10,000 per 
DALY averted in Ethiopia, without forgetting issues with transferability of CEA 
results from one setting to another (46). This means that by choosing to invest a 
dollar on dialysis, one is letting go a potential health gain of about 150 times more 
(ICER of dialysis/ICER of medical primary prevention = US$ 10, 000 per DALY 
averted / US$ 67 per DALY averted) that the Ethiopian population could have 
achieved if the same resources were used to scale-up medical primary prevention of 
CVD at > 35% risk level instead of the dialysis. This is the rationale behind the 
strong recommendation of The Lancet Commission on investing in health that stated 
that low-income countries should first aim for universal coverage of what the WHO 
called the “best-buy NCD interventions” during the initial phase of the fight against 
the rising NCD burden in those settings (5, 103). The “best-buys”— which include 
most of the interventions that we assessed except the packages that contain PCI for 
acute myocardial infarction—were shown to be highly effective, highly cost-
effective, and feasible to be implemented within the existing health infrastructures in 
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low-income settings without the need for complex and highly skilled delivery 
platforms (5, 103).  
Having said this, I acknowledge that cost-effectiveness is not the sole criterion to be 
considered in resource allocation decisions and hence, results from CEAs are not to 
be used in a formulaic manner. Typically, priority setting decisions are informed by 
other criteria regarded as valuable by the society. Some services that ranked lower on 
the basis of CEA might assume higher priority when other criteria are taken into 
account. In the next section, I discuss the results from study III, where we examined 
the expected FRP gains—one of the key additional criteria for priority setting 
decisions—of publicly financing multidrug therapy for primary prevention of CVD to 
individuals with an increased absolute risk of developing CVD events. 
 
5.2.3 Health benefits and financial risk protection from 
cardiovascular disease prevention (Paper III) 
Building on study I and II, in study III, we estimated the expected health and FRP 
gains from UPF of medical prevention of CVD and showed that significant health 
and FRP gains favoring the poorer households could be achieved from the policy. 
Our findings confirm the existing knowledge that the ECEA methods provides a 
useful tool to assess the impact of policies targeting conditions with a gradient across 
population sub-groups (as is the case with CVD risks in Ethiopia) and that it is more 
applicable for health policy analysis in health financing systems where OOP 
payments have a significant role (1, 5, 22, 49, 56, 179).  
This study is one of the few but growing body of ECEAs in Ethiopia (57, 132-136) 
and the first for CVD strategies that was largely based on primary data collected from 
a local setting. Ideally, evidence on a broad range of interventions would be needed to 
make sensible priority setting decisions. We have provided a detailed discussion of 
how our results compare with existing ECEAs from Ethiopia and elsewhere in paper 
III (179).  
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To give a brief account here, the health and FRP gains in our study are larger and 
more pro-poor that what Watkins et.al., estimated from UPF of a salt policy among a 
cohort of one million South Africans (179). We standardized our study population to 
1 million to ensure comparability with Watkins’ et al., and estimated that for a 90% 
incremental coverage, about 2,860 cases of IHD and stroke (compared to 720) and 
1,980 cases of CHE (compared to 75) would be averted in our study population 
compared to what Watkins et al., estimated (179). Respective estimates for a 20% 
incremental coverage were 650 cases of IHD and stroke in addition to 460 cases of 
CHE averted. We estimated that about 23% of the CHE averted concentrated among 
the bottom income quintile, while only 13% of the share concentrated among the top 
quintile: compared with a distribution of 3% (among the bottom quintile) and 46% 
(among the richest) in South Africa (179).  
This difference between the two studies can possibly be due to differences in the way 
CVD care is financed between the two settings. In Ethiopia, CVD care is largely 
financed by households through OOP payments. Therefore, in settings like Ethiopia, 
where OOP payments constitute a great share of health financing, UPF would have a 
key role in protecting the poorest households from financial risk. By contrast, in 
South Africa, CVD care is offered for free or at a highly subsidized rate for the 
poorest households (179). Therefore, the better-off benefited the most from the UPF 
policy because they tend to incur high OOP payments as a result of their greater 
demand for health care and their preference for costly private care settings (179). 
Moreover, the socio-economic gradient in CVD incidence, health service utilization, 
and probability of CHE drive the distribution of the expected FRP gains from the 
policy in our study (94, 100, 145, 161).  
Verguet et al., estimated that for a 20% incremental coverage substantial FRP gains 
from UPF could be attained for selected interventions in Ethiopia: antihypertensive 
treatment (1,200 cases of poverty averted per US$ 2 million invested, US$ 1,700 per 
poverty case); malaria treatment (460 cases of poverty averted per US$ 1.1 million 
invested, US$ 2,200 per poverty case); diarrhea treatment in under-5 children (40,000 
cases of poverty averted per US$ 75 million invested, US$ 1,875 per poverty case); 
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pneumonia treatment in under-5 children (23,000 cases of poverty averted per US$ 
47 million invested, US$ 2,000 per poverty case); caesarian section (410 cases of 
poverty averted per US$ 570,000 invested, US$ 1,400 per poverty case); and TB 
treatment (6,700 cases of poverty averted per US$ 9.5 million invested, US$ 1,400 
per poverty case). Although direct comparison is not possible, UPF of medical 
primary prevention of CVD seemed to be as efficient as anti-malaria treatment and 
pneumonia treatment in purchasing FRP benefits, while the other interventions 
seemed to be more efficient in purchasing FRP gains than the CVD policy that we 
evaluated. Partly, this could be due the higher utilization assumptions that Verguet et 
al., used in their models compared to ours (57). Johansson et al., reported very low 
FRP gains from a UPF policy on mental health interventions in Ethiopia because of 
low service availability and utilization (133). 
“Equity-efficiency” and “FRP-efficiency” trade-offs, when they arise, are difficult 
questions to address for resource allocation. For example, a s briefly highlighted in 
the introduction (section 1.2.3), the intervention under consideration for expanded 
coverage could fare favorably both from health and FRP perspectives or alternatively, 
it could have a diverging performance with respect to the two concerns—potentially 
requiring trade-offs to be made in the final decisions. Here, I use Figure 1 presented 
earlier (see section 1.2.3) to examine possible trade-offs and discuss some suggested 
decision rules to handle the trade-offs in the literature.   
“High health benefits and high FRP” quadrant: the intervention under consideration 
performs well with respect to both health-maximization and FRP perspectives. This is 
a win-win situation where there is no trade-off to be made. A typical example is a 
situation where OOP payments exist even for basic high priority low cost services in 
low-income settings. Improved coverage such services through UPF will improve 
both health and FRP benefits significantly (2). Among the interventions that we 
assessed, medical primary prevention of CVD seems to fall under this category to a 
great extent.  
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“High health benefits and low FRP” quadrant: represents a scenario where the 
intervention considered does well with respect to health benefit maximization, but 
less so from FRP perspective. In this scenario, diverging recommendations have been 
forwarded by experts. The WHO’s commission of equity and UHC recommended 
that interventions such as this deserve may deserve higher priority on the grounds that 
health ought to have higher weight than FRP as a priority ranking criteria of health 
services. The Commission forwarded two key arguments in support of their 
recommendation: 1) on the basis of the intrinsic value of health for one’s wellbeing, 
they hypothesized that it is better for someone to be impoverished (used as a measure 
of FRP) than to die (as a measure of health); and 2) being healthy provides FRP 
indirectly—by protecting the individual from potential future expenditures on health 
care if one gets sick and by improving individuals productivity and income-earning 
potential (2).  
“Low health benefits and low FRP” quadrant: in this scenario, the intervention can be 
ignored safely with no trade-off required. 
“High FRP and low health benefits” quadrant: in this scenario, the intervention under 
consideration confers high FRP benefits coupled with low return from the benefit 
maximization perspective. This is the commonly thought of scenario when FRP is 
discussed and it is generally favored by pro-FRP groups. Generally, there is no clear 
cut direction on how to handle such trade-offs. WHO’s Commission warned that such 
choices might result in an unprecedented loss in total health and choices such as this 
are inconsistent with the fairness principle categorized their report titled “ Making a 
fair choice on the path to UHC” as the “unacceptable trade-off # 2”—“to give high 
priority to very costly services whose coverage will provide substantial FRP when the 
health benefits are small compared to the alternative less costly services” (2). Michael 
Hoel suggested to give higher priority to the alternative, with a rationale that costly 
services with high FRP impact should be prioritized over low-cost services for public 
financing in the absence of universal coverage (180). An example of this scenario 
from our study could be the public finance of PCI for acute myocardial infarction 
which is costly and hence, is expected to have high FRP impact at the individual 
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level. In a related scenario, where interventions have comparable cost-effectiveness 
but differ with respect to FRP, Peter Smith suggested the one that generates better 
FRP gain should be given higher priority (55).  
So far I have discussed the findings of the three studies in comparison with the 
literature, where we showed that seeking CVD care is a financial risk to households 
in Addis Ababa (study I), and that there is a cost-effective CVD prevention strategy 
that Ethiopia could consider for a potential scale-up (study II), and that this cost-
effective intervention could also procure substantial health and FRP gains that would 
preferentially benefit the poor at a modest budget requirement (study III). To reflect 
on priority setting in Ethiopia more generally, the health care financing trend 
indicates a continuing challenge of resource scarcity in the years to come; total 
spending on health grew from US$ 4 (in 1996) to US$ 29 (in 2014) in per capita 
terms (106, 108). Besides, the emerging demographic and epidemiologic transitions 
call for an appropriate response. Therefore, choosing an optimal mix of interventions 
that respond to the needs of the population is crucial to maximize the population 
health within the available budget. However, the response to the evolving health 
needs has to be done in a fair manner taking into account the multiple concerns 
relevant for the Ethiopian context including those discussed in this thesis but not 
limited to them. Among other things, actual priority setting decisions are shaped by 
the institutional capacity of the health system to accommodate the proposed 
intervention, the transaction cost associated with adopting the proposed intervention, 
and feasibility of scale-up (10, 172). In view of this, the multidrug regimen for 
primary prevention of CVD could be scaled-up relatively easily through the existing 
solid primary health care infrastructure.  
5.3 Strengths and limitations 
In the methods section, I have provided a short account of the background and the 
rationale behind our choice of the analytic approaches and the outcome parameters 
that we used to measure health and FRP gains. In addition, methodological issues 
were discussed in detail in each specific paper. Here, I mainly focus on the key 
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methodological strengths and weaknesses that were not well covered previously and 
highlight the most important ones. 
5.3.1 Data availability 
One of the strengths of this dissertation is that the three studies we conducted to a 
large extent benefited from primary data collected from a local setting (e.g., data on 
OOP expenditure that we used in study I and study III, cost of laboratory tests and 
salary for human resource in study II). However, to meet the huge data requirement 
of economic evaluations, we had to complement the primary sources with data from 
multiple sources including assumptions based on expert opinion (e.g., coverage of 
CVD care), data from other settings, or old data from local sources. This may have 
important implications for the robustness of our results. For example, estimates of 
efficacy of interventions used in study II and III were drawn mostly from meta-
analysis of randomized control trials in developed settings; epidemiology of CVD 
risk factors in study III was drawn from an old study conducted in 2006; CVD care 
utilization gradient across income quintiles in study III was drawn from a national 
level data from 2003; unit cost of drugs in study II from international drug price data.  
In order to examine the robustness of our results in the face of these limitations, we 
did sensitivity analysis and characterized the potential impact of such uncertainties on 
our findings. In study II and III, we did one-way sensitivity analysis varying the 
values of each selected parameter (e.g., efficacy of intervention, unit cost 
assumptions, or coverage level) at a time to estimate their expected impact on the 
results. Whereas, probabilistic sensitivity analysis was undertaken in study II to 
assess the combined effect of multiple parameters (e.g., costs and effects) 
simultaneously (40). However, this weakness is inevitable and can only be improved 
by doing more research to improve availability of locally relevant data (e.g., on 
efficacy of interventions, health service utilization, and epidemiology of CVD and 
risk factors) in a timely manner. For example, the EPHI completed a national STEPS 
survey in 2015. However, the raw data was not yet made available at the time we did 
the analysis for the papers.   
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5.3.2 Study design issues  
In order to trace the impact of OOP expenditures for CVD care on household 
economy, it would have been better to adopt a longitudinal study design and follow 
households over a reasonable period of time. However, this was not possible for 
practical reasons. Instead, we conducted a cross-sectional cohort study where we 
asked households to report expenditures on the day of data collection as well as 
retrospectively over a 12-month recall period with a detailed breakdown of cost 
items—this can be considered a strength given the study design.  
The choice of the recall-period and number of cost-items (expenditure breakdown) 
have important implications to the validity and reliability of OOP expenditure 
estimates (181). There is no gold standard framework for such design issues (182). 
However, more breakdowns and shorter recall periods tend to lead to higher estimates 
for OOP expenditures (181, 182)—although validating whether higher OOP estimates 
mean closer to the truth (“true expenditures”) or not remains to be a methodological 
challenge (181). Generally, shorter recall periods are assumed be better to memorize 
previous expenditures (183), while a more detailed cost breakdown has a prompting 
effect on respondents that reduces the risk of misunderstanding and improves 
reporting accuracy (182). Whereas with longer recall periods, one would be able to 
capture more information, especially if non-uniform expenditure patterns are 
expected (a typical scenario with chronic diseases such as CVD). Some have shown 
that the longer the period between the event (the expenditure) and interview date is—
there is higher tendency to omit details and misreport information (183). However, 
Clarke et al., argues that shorter recall period does not necessary mean good. It 
depends on the outcome we are interested in and the policy relevant (meaningful) 
period, among other things. As a consequence, trade-offs have to be made to balance 
precision (which is assumed to be better with short recall period) and the potential 
information loss (which improves with longer recall periods) (184). Therefore, 
innovative solutions are much needed (181) to help guide with the decision about 
these trade-offs. In our case, given the chronic nature of CVD, we used a 12-month 
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recall-period with an 8-item breakdown of expenditures to mitigate some of these 
study design issues.  
Another limitation that emanates from the specific study design pertains to the 
“hospital-based cross-sectional cohort” nature of study I from which estimates of 
OOP expenditure and probability of CHE were drawn for of study I and III. As 
discussed in the methods section, hospital-based studies have inherent limitation to 
fully capture the financial burden that households face due to the prohibitive impact 
of direct OOP payments. This is because reported OOP payments tend to be 
presumably low when households do not use health services—which translate to low 
magnitude of financial risk as measured by parameters such as CHE. As a results we 
might have under-estimated the magnitude of financial risk in study I and the 
potential FRP gains in study III. We acknowledge this as one important inherent 
limitation of the study design which we cannot avoid fully. 
5.3.3 Internal validity 
Internal validity of the study is concerned with the extent to which the study measures 
what it intends to measure—can one make sensible conclusions about the study 
population (185)?  The way we selected the study population and collected the 
information have important implication to the validity our findings (particularly for 
study I and III). Details about the selection procedure, the rationale for our choice, 
and the possible implications of factors related selection have been discussed at 
length in paper I. Here, I focus on a couple of issues related to measurement.    
With regards to the measurement of households’ living standards (in papers I and III), 
although consumption expenditures are generally assumed to better reflect 
individuals’ or households’ living standards in low-income settings, we used reported 
income instead. This is because half of the study participants were men (less 
informed than women about consumption expenditures in the Ethiopian setting) and 
were working in the formal sector. Therefore, reporting income was relatively easier 
for them compared to consumption expenditures. However, in settings where 
households rely to a greater extent on the informal economy, reported income is 
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considered a less reliable measure of living standards (22). Moreover, in settings 
where home-grown products represents a huge part of household consumption, 
reported income under-represents living standards. Therefore, consumptions are 
assumed to reflect household economic conditions better. Another advantage of 
consumption is that, households use several coping mechanisms (e.g., use of savings) 
to smoothen potential fluctuations in the face shocks (health or income)—which is 
less well reflected in pure income measurement (22). In order to mitigate some of 
these methodological challenges with reported income, we collected data on the 
coping mechanisms that households used to finance OOP payments for CVD care and 
explored its impact on financial risk as discussed in previous sections and in paper I. 
Furthermore, in order to assess factors associated with CHE, we used widely applied 
logistic regression models. However, odds ratios do not predict “risk” well when the 
outcome of interest is common—which is often defined as prevalence of the attribute 
of interest more than 10% (146). In our case, 27% of households had CHE. 
Therefore, care should be taken not to make firm conclusions about the estimates of 
the strength of association between the dependent variable (CHE) and the covariates. 
5.3.4 External validity 
External validity refers to the generalizability of the findings of the study beyond the 
population studied (185). Generalizability of our findings to other relevant 
populations (e.g., rural population in Ethiopia or populations in other low-income 
settings) depends to a large extent on how similar (representative) the population we 
studied is with those broader populations that we intend to extrapolate or apply our 
findings to. Therefore, one needs to compare the population we studied with the 
broader population with respect to factors that have important implication to the 
outcome of interest (e.g., demography, CVD and risk factor epidemiology, health 
service utilization, and cost of services). Study I and III are sub-national studies from 
Addis Ababa largely based on hospital-based survey data, while study II is a 
modeling exercise (CEA) at the national level. Therefore, the generalizability of our 
finding to the broader Ethiopian population may be deemed limited given the 
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important differences between the population in Addis Ababa and the rest of the 
country which is largely rural and have limited access to CVD care. Some of the 
differences include higher prevalence of CVD and its risk factors, better educated 
largely adult population, better access to CVD care (availability), better health service 
utilization, and higher cost of health care in Addis Ababa than the rest of the country 
(16, 65, 86). However, given the fact that 20% of the study population were from 
different parts of the country outside the capital, our findings could still be considered 
relevant to the national level priority setting decisions. In addition, our finding may to 
a certain extent apply to populations in the capitals of other low-income settings that 
have similar epidemiological and health service availability and utilization pattern as 





In this thesis, we sought to assess the health outcomes, costs, and FRP of CVD 
interventions so as to inform priority setting decisions for health care in Ethiopia.  
This study uncovered the existence of substantial financial risk that households face 
when seeking prevention and treatment of CVD in hospitals in Addis Ababa—where 
more than a-quarter (27%) of the households suffered financial catastrophe with an 
annual OOP spending on CVD care of more than a-tenth of households’ annual 
income. The poorest, those with an established CVD event especially stroke, those 
that were hospitalized, and households that travelled to Addis Ababa to seek CVD 
care were among the most affected.  
Moreover, the study showed that primary prevention of CVD with a basic multidrug 
regimen consisting of aspirin, antihypertensive, and statins to be the most cost-
effective intervention (at all risk levels) compared with treatment and secondary 
prevention interventions for CVD that we assessed. Respective ICERs for this 
preventive package ranged from US$ 67 per DALY averted (at > 35%) to US$ 340 
per DALY averted (at > 5%) absolute risk levels.          
Lastly, we demonstrated that UPF of primary prevention of CVD with a basic 
multidrug regimen could lead to more than just efficient purchase of health. In total, 
the UPF policy would avert about 850 cases of CHE per year, in addition to averting 
5,800 DALYs at an estimated annual cost of US$ 1.9 million. The distribution of 
both the health and FRP gains would favor the poorer households, where nearly 90% 
of these gains accrued to the bottom four quintiles in general, and about 20% of the 
total gains benefited the poorest quintile compared with roughly 10% of the share 
among the richest quintile at all risk levels. Therefore, the UPF of medical primary 
prevention is an attractive strategy worth considering for public financing in Ethiopia 
as it addresses key health system concerns, such as FRP and distributional concerns, 
in addition to its cost-effectiveness. I, therefore, conclude that primary prevention of 
CVD saves more than lives in Ethiopia.  
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7. Implications 
7.1 Implications for future practice  
Many ethicists agree that it is unethical to ignore the need for a systematic priority 
setting of scarce health care resources (8, 24). Priority setting, in turn, requires a set 
of widely agreed criteria that guide such decisions informed by a solid evidence base 
and through transparent processes (8). Evidence on economic evaluation of health 
interventions is at the heart of priority setting decisions. In this thesis, I discussed 
economic evidence that we generated pertaining to CVD care in a low-income 
country where there is a growing but still limited local capacity to undertake 
economic evaluations. Such evidence was lacking in Ethiopia and needs to be filled 
to improve health care resource allocation decisions. Our findings would help to 
better understand the financial risk related to seeking CVD care and the expected 
investment return from scaling-up selected CVD interventions with respect of health, 
FRP, and distributional consequences—which in turn facilitate the explicit 
examination of the trade-offs between multiple health policy objectives in Ethiopia.   
However, the continuous and evolving nature of priority setting decisions with 
changes in the disease epidemiology, demography, coverage of services, costs, and 
availability of resources requires ensuring a sustained availability of good quality 
evidence reflecting those developments (10). With this regard, I see two broader 
challenges that need to be dealt with in Ethiopia. First, the issue of local capacity to 
generate evidence relevant for policy and priority setting—this includes but not 
limited to economic evaluations (e.g., data on epidemiology, unit costs, service 
utilization etc.). Furthermore, in as much as striving to generate local evidence by 
conducting new studies or surveys, timely data sharing practice is also important to 
optimally utilize the existing resources.  
Second, in addition to generating evidence, translating the evidence in to practice is 
needed. Therefore, the process of evidence generation needs to be followed up with 
the appropriate next steps to for optimal use of the evidence produced. To this end, a 
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10-step framework has been proposed for a sound priority setting steps to define and 
implement a prioritized health benefit package (186). A key requirement is therefore 
institutionalizing priority setting through mechanisms such as the UK’s National 
Institute for Health and Care and Care Excellence. Recently, the FMOH has 
established a Health Economics and Financing Analysis case team which may 
assume a leading role in the institutionalization the priority setting functions for the 
health sector in Ethiopia.   
In a related matter, studies including from developed settings have shown the limited 
role of economic evaluations in informing actual priority setting decisions (10, 187). 
Several reasons were cited for this gap including the lack of timeliness of CEAs, lack 
of sensitivity of CEAs to the decision context, and methodological limitations. 
However, economists strongly concur that the use of CEAs with all its imperfections 
is by far better than implicit priority setting decisions (21).  
7.2 Recommendations for future research 
Given the challenges to memorize OOP expenditures over the long term, the 
uncertainty surrounding what might be an ideal recall-period, and the desirable level 
of detail of cost items reporting, I believe that randomized controlled trials of mobile 
phone based data collection systems could help answer some of these question and 
lead to a potential revolution in OOP expenditure data collection.      
In addition, more research is needed to further develop mechanisms that would help 
incorporate FRP in priority ranking of health services. Although a potential 
application of indifference curves to explore possible trade-offs between health 
maximization and FRP gains have been suggested (57), further research is highly 
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